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Antisense oligonucleotides (AOs) are a class of nucleic acid molecule that can specifically bind 
to RNA targets and subsequently modulate gene expression by different mechanisms of action. 
AOs composed of natural nucleotide monomers are not suitable for clinical applications as they 
are vulnerable to nuclease degradation and possess relatively low target binding affinity. To 
overcome these impediments, chemically-modified nucleic acid analogues are used to improve 
AO resistance to nuclease degradation, and target binding affinity. AO-mediated splice 
modulation has been emerged as a potential treatment approach for different genetic diseases, 
especially in Duchenne muscular dystrophy (DMD)- an X-linked inherited recessive condition 
arising from protein-truncating mutations in the dystrophin gene. By blocking the interaction 
between splicing factors and pre-mRNA, AOs can be used to correct genetic defects by 
manipulating splicing (exon deletion or inclusion). 
This thesis explores the synthesis and screening of various chemically-modified splice-
modulating AOs in different cellular models. Chapter 1 provides a broad overview of various 
nucleic acid therapeutic technologies and the significance of chemically-modified 
oligonucleotides in drug development. Chapter 2 focused on the evaluation of various 
chemically-modified nucleotide-modified exon-skipping AOs in DMD. For this purpose, AOs 
incorporated with various chemically-modified analogues were designed, synthesised and 
tested their ability to induce exon-23 skipping in mouse dystrophin gene transcript in vitro. 
The focus of Chapter 3 was to develop novel splice-modulating AOs targeting Vascular 
Endothelial Growth Factor (VEGF) towards tackling solid cancers. VEGF is a key regulator 
in angiogenesis- a process that implicated with cancer development, and in this study we 
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developed novel splice-modulating AOs to inhibit the expression of VEGF and evaluated their 
efficacy in different cancer cells in vitro.  
Overall, the findings in this thesis show promising potential of chemically-modified 
nucleic acid analogues in developing splice-modulating AOs. The results presented here 
highlight the scope of chemically-modified splice-modulating AOs towards developing 
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Chapter 1.  












1. Nucleic acid technologies: overview and mechanisms of action 
Friedrich Miescher laid the foundation for nucleic acid technology with the discovery of a 
novel molecule isolated from the cell nucleus called “nuclein” [1,2]. Subsequent studies have 
clarified Miescher’s findings and called the molecule “nucleic acid” due to its acidic properties 
[1]. The most important breakthrough in nucleic acid biology was achieved in 1953 when 
Watson and Crick successfully solved the double-helix structure of deoxyribose nucleic acid 
(DNA) molecule [3]. Current knowledge supports the existence of two types of nucleic acid 
molecules: DNA and ribose nucleic acid (RNA). Both DNA and RNA molecules composed of 
polymers of building blocks called nucleotides. Each nucleotide building block contains a sugar 
ring, a nitrogenous base (nucleobase), and a phosphate group (Figure 1.1). There are two types 
of nucleobase: purine (adenine (A), guanine (G)), and pyrimidine (cytosine (C), thymine (T) 
and uracil (U)).   
 
 




One fundamental problem in the early days was to establish a comprehensive connection 
between DNA, RNA and protein [4,5]. Francis Crick unraveled the problem by introducing the 
basic concept of molecular genetics, “The Central Dogma”, which often simplified as: “DNA 
makes RNA makes protein.” (Figure 1.2) [4-6]. 
 
 
Figure 1.2 The central dogma of molecular genetics. 
 
The rapid development of nucleic acid field required the establishment of a synthetic 
strategy of oligonucleotide. In fact, the synthesis of polynucleotide had been started in the 
1950s based on enzymatic reaction of phosphorylase [7]. The real breakthrough for the 
technology came when Khorana and colleagues demonstrated the first successful chemical 
synthesis of a sequence-defined oligonucleotide in 1958, an achievement widely regarded as 
the birth of synthetic nucleic acid technology [8,9]. However, this process was inefficient due 
to its low yield and labour demands. The next leap forward was then achieved in 1981 by 
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Caruthers and coworkers who developed phosphoramidite chemistry to synthesise 
oligonucleotide, an approach that has become the most widely used method for oligonucleotide 
synthesis (Figure 1.3) [10,11]. A comprehensive review on the history of oligonucleotide 
synthesis technology can be found elsewhere [12]. 
 
 
Figure 1.3 Phosphoramidite oligonucleotide synthesis cycle. The DMTO protecting group 
is removed from the first nucleoside (detritylation), allowing reaction with the next nucleoside 
(activation and coupling). This complex is then oxidised to create a stable species under acidic 
condition (in preparation for the next cycle) before the unreacted 5′-hydroxyl groups were 




In the last two decades, improvements in the synthesis and purification techniques have 
allowed oligonucleotides to be synthesised in large scale with high yield and good quality. 
These advances have driven the remarkable progress of nucleic acid technology in theranostic 
development. Following the approval of Vitravene by the US Food and Drug Administration 
(FDA) in 1998 for the treatment of cytomegalovirus retinitis (CMV) in immunocompromised 
patients [13], four more oligonucleotide drugs have reached the market: Macugen (2000) for 
the treatment of neovascular (wet) age-related macular degeneration (AMD) [14], Kynamro 
(2013) for the treatment of homozygous familial hypercholesterolemia [15], Exondys-51 
(2016) for the treatment of Duchenne muscular dystrophy (DMD) [16] and Spinraza (2017) for 
the treatment of Spinal muscular atrophy (SMA) [17,18]. There are different classes of nucleic 
acid therapeutic molecules with distinct mechanism of action. Based on the RNA targeting 
mechanism of action, these molecules can be classified into five main categories: 1) antisense 
oligonucleotide (AO); 2) short interfering RNAs; 3) miRNA targeting (anti-miR); 4) Ribozyme 
(RNAzyme/ DNAzyme); and 5) aptamer. In this chapter, these categories are comprehensively 
discussed with a focus on their mechanism of action and theranostic potential. 
 
1.1 Antisense oligonucleotides  
Antisense oligonucleotides (AOs) are short single-stranded oligonucleotides (usually 15-30 bp 
in length) that can specifically bind to RNA targets through Watson-Crick complementary base 
pairing [19]. Stephenson and Zamenik first demonstrated this concept in 1978 by successfully 
inhibiting Rous sarcoma virus 35S RNA translation with a tridecamer DNA AO [20]. In the 
years that followed, novel AO strategies have been proposed and investigated for therapeutic 
efficacy. Once annealed, different modes of AO action are evoked, depending upon the 
oligonucleotide chemistry, inducing RNase-H degradation of a mature mRNA, imposing steric 
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bulkiness to block protein translation, promoting gene silencing or manipulating splicing of the 
pre-mRNA [21,22]. These AO mechanisms can be exploited or adapted to treat various 
disorders including inherited genetic disorders. 
 
1.1.1 RNase-H mediated degradation 
The mammalian RNase-H nuclease family consists of two naturally occurring proteins: RNase-
H1 and RNase-H2. Previous studies suggest that only RNase-H1 participates in the AO-
mediated cleavage of RNA, while RNase-H2 is tightly bound to chromatin [22,23]. Once 
entered the cell cytoplasm, AO binds to the complementary region in the target mature mRNA, 
thereby creating a DNA/RNA hybrid with unique properties that can be recognised by RNase-
H1 nuclease. The nuclease then cleaves the RNA by hydrolyzing one of its internucleotide 
phosphate linkage, resulting in the ablation of target gene expression (Figure 1.4) [22,23]. 
Although the exact mechanism for RNase-H mediated hydrolysis is not yet known, models 
have been proposed. For instance, Ho et al. have suggested that a two-metal catalyst may 
facilitate the reaction [24]. In addition, the flexibility of the DNA/RNA duplex was also 
responsible for RNase-H activity. AO-induced RNase-H degradation is now being widely 





Figure 1.4 Simplified schematic illustration of RNase-H mediated degradation shows the 
binding of AO to target mRNA following by the recruitment of RNase-H1 that results in 
the cleavage of mRNA. 
 
1.1.2 Steric block  
Steric block effects by the AO can be achieved through different mechanisms. In mammalian 
cells, before mRNA can be translated to protein, it must be first recognised and bound by the 
ribosome and other proteins of the cellular machinery. If an AO physically blocks the binding 
motifs of these components, it can arrest translation and thereby inhibit protein production [26]. 
Common AO design strategies include blocking of the ribosome binding site, 5’ cap site or 
translation initiation site in the mature mRNA (Figure 1.5) [21]. 
 
 
Figure 1.5 Simplified schematic illustration of AO steric block shows the physical block 




1.1.3 AOs targeting pre-mRNA - splice-switching AOs 
Strategically, AO can be designed to target pre-mRNA and interfere with RNA processing 
events such as splicing or nuclear polyadenylation. Pre-mRNA splicing is an important process 
in regulating gene expression [27]. By variably removing introns and some exons from the 
primary gene transcript, splicing can generate a range of different mature mRNA variants from 
a single type of pre-mRNA transcript, resulting in differential protein expression. Splicing takes 
place inside the nucleus and is driven by a highly dynamic, multimolecular ribonucleoprotein 
(RNP) complex called the spliceosome, which is sophisticated enough to accurately and 
flexibly recognise and select splice site [28,29]. Splicing enhancers and silencers, proteins that 
bind to sequence motifs in the pre-mRNA exons and introns, play a significant role in 
regulating this process. However, splicing errors can arise from mutations in these motifs, often 
giving rise to genetic diseases. Introduction of splice-switching AOs can therapeutically 
manipulate defective splicing. Once administered, an AO targeted to a splicing motif in the pre-
mRNA will sterically block the binding of splicing factors and thereby alter subsequent 





Figure 1.6 Simplified schematic illustration of splice-switching AOs physically block the 
binding motif of splicing factors causing either exon-skipping or exon-inclusion. 
 
In addition to spicing motifs, AOs can be targeted to other sites in the pre-mRNA such as 
the polyadenylation signal sequence, cleavage/polyadenylation specificity factor (CPSF) or 
cleavage stimulation factor (CstF), halting these processes and inducing mRNA degradation or 
translation arrest [30,31]. To date, two splice-switching AO drugs have been approved by the 
US FDA: Exondys51, which utilises exon-skipping to partially rescue the DMD function in 
some patients by deleting exon 51 in the dystrophin gene transcript and produce partially 
functioned dystrophin [16]; and Spinraza, which improves survival motor neuron (SMN) 
protein production in spinal muscular atrophy patients by inducing inclusion of exon 7 in their 
SMN2 transcripts [17]. 
 
1.2 RNA interference 
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RNA interference (RNAi) is an important gene silencing mechanism. First discovered in 1993 
by Ambros and colleagues [32] as “small regulatory RNAs” in Caenorhabditis elegans, RNAi 
was later described as a mechanism of “potent and specific genetic interference by double-
stranded RNA” [33]. Subsequent studies have classified RNAi into two categories: small-
interfering RNAs (siRNAs) and microRNAs (miRNAs) [34-36]. Briefly, when a long dsRNA 
molecule (>23 bp) is introduced into a cell’s cytoplasm, it is recognised and hydrolysed by the 
Dicer enzyme into short dsRNA molecules, thereby generating either siRNA (21-23 bp, 3’ two-
nucleotide overhang) or miRNA (18-25 bp, no overhang nucleotide). These molecules then 
associate with the RNA-induced silencing complex (RISC) containing Argonaute-2 enzyme 
which cleaves the sense strands and guides the antisense strands to their target mRNA for 
facilitating post-transcriptional gene silencing (Figure 1.7) [33]. Although siRNA and miRNA 
share several common features, there are a few major distinctions between them. While siRNA 
can be fully complementary to any part of the mature mRNA, miRNA is often partially 
complementary to the 3’ untranslated region (UTR). In addition, miRNA is able to trigger 
either translational repression, deadenylation or degradation of the target mRNA, whereas 




Figure 1.7 Simplified schematic illustration siRNA and miRNA mechanisms of action. A. 
siRNA-mediated degradation of target mRNA; B. miRNA-mediated inhibition of target 
mRNA. 
 
By mimicking the characteristics of these naturally occurring platforms, researchers have 
been able to generate novel classes of therapeutic agents: synthetic siRNAs and miRNA 
mimics. Their findings indicate that the length of a siRNA has a significant impact on the 
strength of its silencing effect. For instance, a 27 bp siRNA is 100 times more efficient than a 
21 bp siRNA, but siRNAs longer than 30 bp can induce the interferon pathway and should 
therefore be avoided [34]. On the other hand, the design of miRNA is more straightforward, as 
any identical antisense strand to that of the miRNA is considered miRNA mimic. siRNAs and 
miRNA mimics are now widely used as therapeutic approaches to treat genetic diseases [34]. 
 
1.3 Micro-RNA targeting (anti-miR) 
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As discussed in the previous section, miRNAs are a class of non-coding RNA that function in 
gene silencing. Sequence-specific inhibition of miRNAs can be achieved by designing AOs 
complementary to the miRNA antisense strand (Figure 1.8) [36]. The AO/ miRNA hybrid 
binding affinity and nuclease resistance can be enhanced with the use of chemically-modified 
nucleic acid analogues. A comprehensive view of these chemical modifications will be 
discussed in the latter part of this chapter. 
 
 
Figure 1.8 Simplified schematic illustration of anti-miR inhibiting miRNA function by 
competing with the mRNA. 
 
1.4 Ribozyme (RNAzymes/ DNAzymes) 
Ribonuclease enzyme, or ribozyme, was first described in 1982 as “an RNA molecule that has 
the intrinsic ability to break and form covalent bonds.” [37]. Ribozymes possess enzyme-like 
characteristics in the presence of divalent metal ion cofactors (such as Mg2+ or Ca2+) [38]. In 
1994, Ronald Breaker and Gerald Joyce reported a “DNA enzyme that cleaves RNA”, or 
DNAzyme, that showed higher catalytic activity compared to RNAzyme [39]. The simple 
structure of a ribozyme includes two binding arms for specific target mRNA binding, and a 
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catalytic core that cleaves the target [40], and are generated through a process called in vitro 
selection [40]. The two most popular designs of a ribozyme are 10-23 motif (hairpin) and 8-17 
motif (hammerhead), established by Santoro and Joyce in 1997 (Figure 1.9) [41]. 
 
 
Figure 1.9 Hairpin (10-23) ribozyme (left) and hammerhead (8-17) ribozyme (right) 
cleavage of target mRNA. (R=A or G, Y=C or U). 
 
One unique characteristic of ribozymes is their reusability, as the process of ribozyme-
mediated cleavage is reiterative [40]. Chemically-modified nucleic acid analogues can also be 
incorporated into ribozyme to enhance the stability and catalytic activity [42]. Schubert and 
colleagues reported that the incorporation of 2’-O-methyl RNA and locked nucleic acids 
(LNA) monomers into the binding arms of DNAzyme improved target recognition and 
cleavage efficiency [43]. Chakravarthy et al. recently demonstrated that introducing inverted 
dT and LNA monomers into DNAzyme binding arms can enhance nuclease resistance of the 
DNAzyme which showed better stability [44]. 
 
1.5 Nucleic acid aptamers 
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Aptamers are short, single-stranded synthetic oligonucleotide ligands that achieve high-affinity 
and specific binding of their targets through unique secondary structure [45]. These 
characteristics make aptamers an attractive platform for applications in drug delivery and 
therapeutic development (e.g. blocking target receptors or mediating delivery of a therapeutic 
agent), biosensing (e.g. labelling and detection), and nanotechnology (anchoring and nano-
sensors) (Figure 1.10) [45].  
 
 
Figure 1.10 Applications of nucleic acid aptamer. Nucleic acid aptamer can be utilised to 
detect a target of interest for diagnostic purpose; conjugated with either small molecules or AO 
for drug delivery, or can be used as a dual-targeting approach in both diagnostic and 
therapeutic. 
 
Aptamers are developed using a selection process called Systematic Evolution of Ligands 
by EXponential enrichment (SELEX; Figure 1.11) using a large library of randomly generated 
oligonucleotides (~1015 members) [46-48]. In 2012, Veedu and colleagues reported a rapid 
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one-step selection methodology for developing nucleic acid aptamers to reduce the time 
required to develop aptamer [49].  
 
Figure 1.11 Conventional SELEX cycle. Adapted from Veedu RN and Wengel J. Mol 
Biosyst. 2009 [48]. 
 
2. Nucleic acid chemistries and modifications  
Natural oligonucleotides based on DNA and RNA chemistries are not suitable as therapeutics, 
as these types of molecules are rapidly degraded in vivo and possess relatively poor binding 
affinity. Chemically-modified nucleic acid analogues offer superior therapeutic properties such 





2.1 Chemical modifications  
Over the last few decades, a variety of alternative nucleoside and backbone modifications have 
been developed and refined that enhance the resistance of oligonucleotides to degradation, and 
improve its bio-distribution. 
 
2.1.1  Internucleotide linkages 
In DNA and RNA, the internucleotide linkage consists of a negatively-charged phosphodiester 
backbone (at a pKa of ~2) that this is highly vulnerable to cleavage by serum or cellular endo- 
or exonucleases. Altering the chemistry of these internucleotide linkages can substantially 
improve the stability of the entire moclecule, and several such modifications have been 
developed in recent years. In first-generation modified oligonucleotides, the non-bridging 
oxygen atom of the phosphate backbone is replaced with sulfur, thereby hinders the nuclease 
degradation. These compounds are referred to as phosphorothioates (PS) (Figure 1.12) [50]. 
Recently, Wada and colleagues reported the synthesis of stereocontrolled PS 
oligodeoxyribonucleotides using an Automated Synthesiser []. A number of other linkage 




Figure 1.12 Representatives of internucleotide linkage modifications including 
phosphorothioate (PS), N3’-phosphoramidate, boranophosphate, amide linkage, 
phosphorodiamidate morpholino oligomer (PMO), peptide nucleic acid (PNA). 
 
2.1.2 Sugar modifications 
Modification of the sugar moiety of an oligonucleotide can improve its binding affinity, 
conformational flexibility, and resistance to enzymatic degradation. A number of sugar-
modified nucleotides have been developed in recent years, including 2’-O-Methyl (2’-OMe), 
2’-O-methoxyethyl (2’-MOE) 2’-Fluoro RNA (2’-F), 2’-deoxy-2’-Fluoro-βD-arabino nucleic 
acid (2’-FANA), locked nucleic acid (LNA), unlocked nucleic acid (UNA), tricycloDNA 
(tcDNA), hexitol nucleic acid (HNA), and phosphorodiamidate morpholino oligomer (PMO) 
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(Figure 1.13). The chemistry and properties of these modifications are discussed in detail in 
previous reviews elsewhere [51]. 
  
 
Figure 1.13 Examples of sugar-modified nucleic acid analogues including 2’-O-Methyl (2’-
OMe, 2’-O-2-Methoxyethyl (2’-OMOE), 2’-Fluoro (2’-F), 2’-deoxy-2’-
fluoroarabinonucleotide (2’-FANA), locked nucleic acid (LNA), unlocked nucleic acid (UNA), 
tricyclo DNA (tcDNA), hexitol nucleic acid (HNA). 
 
2.1.3 Nucleobase modifications 
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The purpose of chemically-modified nucleobases (purine and pyrimidine) is to enhance binding 
strength and kinetics of duplexed oligonucleotides. However, alternative nucleobases are not 
as commonly applied as sugar and internucleotide linkage modifications. There are enormous 
numbers of chemically-modified nucleobases and a comprehensive review on these 
compounds can be found elsewhere [51]. Recently, we have explored the use of 5-
(phenyltriazol)-2′-deoxyuridine nucleotides in exon-skipping application in mouse dystrophin 
transcript in vitro [52]. 
 
2.2 AO design 
Majority of research into chemically-modified nucleic acids has focused on mRNA inhibition 
by RNase-H recruitment and steric blocking of translation. These AOs are generally designed 
as gapmer or mixmer constructs (Figure 1.14). In the gapmer design, a central core of natural 
nucleotide monomers (including phosphorothioate modifications) is flanked by short tracts of 
modified nucleotides to enhance RNAse-H mediated cleavage of the target mRNA. In the 
mixmer design, the modified nucleotides alternate with natural nucleotides throughout the AO. 
Mixmers are mainly used for imposing steric bulkiness on their target.  
  
 





2.3 AO delivery and limitations 
For an AO to be effective, it must be efficiently delivered to its target [53]. There are several 
factors that possibly influence the efficiency and biological potency of the AO including 
stability under nuclease condition, specificity and binding affinity to the target, cellular uptake 
and tissue distribution, and toxicity. Different strategies have been proposed to improve AO 
delivery including the use of cell-penetrating peptides or nanoparticles such as liposome 
complexes [54,55]. Another approach is to induce AO uptake through receptor-mediated 
endocytosis. This strategy involves conjugating an AO with molecules such as antibodies or 
aptamers that readily target the surface receptors of barrier cells [56]. In some cases, AO can 
be introduced directly to the target tissues such as intramuscular injection, intravitreal injection 
or intranasal infusion. In recent reviews, pharmacokinetics, biodistribution and cellular uptake 
of AOs have been discussed comprehensively [54,57-59]. 
 
3. Significance and aims of this project 
The successful and ongoing development of AO drugs has highlighted the therapeutic potential 
of chemically-modified nucleic acid analogues. However, only a few of such modifications 
have been explored for exon-skipping application. Our laboratory has substantial expertise in 
designing, synthesising and evaluating modified exon-skipping AOs. In the first part of this 
thesis, a range of novel AO chemistries were considered for evaluation of their efficacy in 
inducing exon-skipping. Splice-switching AO has been extensively studied in diseases such as 
DMD and SMA. So far, there has been only one report on using exon-skipping in cancer 
therapy. Therefore, another focus of this thesis was to develop novel splice-switching AO 
targeting Vascular Endothelial Growth Factor (VEGF) towards tackling solid cancers, which 
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has resulted in a provisional patent, application submitted to Australian patent office 
(2018901653).  
 
Aims of this study 
The overall foci of this study are to explore novel chemically-modified exon-skipping AOs in 
vitro in Dmd model, and to develop novel exon-skipping AO strategy for talking solid cancers. 
To achieve this, the following specific aims are addressed: 
1. To design, synthesise and evaluate AOs incorporated with various chemically-modified 
nucleic acid analogues to induce exon-23 skipping in mouse dystrophin gene transcript 
in vitro. 
2. To design, synthesise and evaluate novel exon-skipping AOs targeting VEGF gene 
transcript towards tackling solid cancers using various cancer cellular models. 
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Chapter 2.  
Exploring novel chemically-modified nucleic acid analogues 
towards improving therapeutic effect of splice-switching antisense 






Antisense oligonucleotides (AOs) are a prominent class of therapeutic nucleic acid that can 
regulate the processing and expression of RNA [1-5].  However, naturally occurring AOs are 
rapidly degraded in vivo and possess poor target-binding affinity. Instead, it has become 
common to introduce chemically-modified nucleic acid analogues to improve AO binding 
affinity and stability against nuclease degradation without stimulating immunological reactions 
[6,7]. Recent clinical translation of novel oligonucleotide therapeutic molecules demonstrates 
that the use of chemically-modified monomers is paramount to improve the pharmacokinetics 
of AO-based therapeutic molecules, and hence crucial for the development of successful 
nucleic acid-based drugs [8]. Although several nucleic acid analogues have been reported in 
recent years, only a few were utilised in drug development. To date, four candidates have been 
approved by the US Food and Drug Administration (FDA) for clinical use such as Vitravene, 
a 21-nucleotide phosphorothioate-modified DNA AO against cytomegalovirus retinitis in 
immunocompromised patients [9]; Kynamro, a 20-nucleotide AO modified with 2′-O-
methoxyethyl-RNA chimera against familial hypercholesterolemia [10]; Exondys 51, a 30-
nucleotide phosphorodiamidate morpholino AO for the treatment of Duchenne muscular 
dystrophy (DMD) [11]; and Nusinersen, a 18-nucleotide AO modified with 2'-O-(2-
methoxyethyl) (2’-MOE) RNA for the treatment of spinal muscular atrophy (SMA) [12].  
To further validate the scope of utilising chemically-modified nucleic acid analogues in 
developing oligonucleotide-based therapy, this chapter describes the design and application of 
novel modified AOs that strategically incorporated with different classes of nucleotide 
monomers such as locked nucleic acid (LNA), anhydrohexitol nucleic acid (HNA), 
cyclohexenyl nucleic acid (CeNA), D-altritol nucleic acid (ANA), twisted intercalating nucleic 
acid (TINA), serinol nucleic acid (SNA) and 5-(phenyltriazol)-2′-deoxyuridine. These AOs 
were designed, synthesised and evaluated for exon-skipping efficiency utilising Duchenne 
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muscular dystrophy (DMD) as a disease model. For this purpose, cultured mouse H-2Kb-tsA58 
mdx (H2K mdx) myotubes that resemble the disease conditions were exploited as an in vitro 
cellular model for testing the AOs performance.  
The first part of this chapter provides an overview of muscular dystrophies and their 
current treatment options including gene targeting therapy. Following that, the disease 
pathologies of muscular dystrophies are elucidated with an emphasis on AO-based therapy. 
The latter part of this chapter describes the study of novel chemically-modified AOs for exon-
skipping application utilising DMD as a disease model. 
 
2. Muscular dystrophies  
2.1 Overview of muscular dystrophies  
Muscular dystrophies (MDs) are a diverse group of inherited muscle diseases (Figure 2.1) that 
may vary from asymptomatic to severe, with symptoms evident at birth or appearing later in 
life [13,14]. Many causative genes have been identified that can give rise to various modes of 





Figure 2.1 Schematic illustration of (A) Dystrophic arm muscle in comparison between 
normal individual and MD patient; and (B) Skeletal muscle anatomy showing muscle 
fiber structure. Adapted from https://ghr.nlm.nih.gov/condition/duchenne-and-becker-
muscular-dystrophy#definition [15]. 
 
The most common and severe form of childhood muscle wasting disorder is DMD, an X-
linked recessive condition arising from protein-truncating mutations in the dystrophin gene 
(DMD) [14]. Another type, the limb girdle muscular dystrophies (LGMD) may manifest as 
autosomal recessive or dominant, with a wide spectrum of severity and age of onset, depending 
upon the gene and causative mutation [16]. Other common forms of MDs include 
Facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant condition arising 
from the loss of a macrosatellite repeat sequence in the sub-telomeric region of chromosome 4 
(4q35) [17] and the myotonic dystrophies (DM1, DM2), highly variable conditions dependent 
upon the gene and the nature of the repeat expansion [18]. DM1 is caused by an expanded CTG 
triplet repeat in the 3ʹ untranslated region (UTR) of dystrophia myotonica protein kinase 
(DMPK) on chromosome 19q13.3, with the subsequent production of a toxic RNA. DM2, much 
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less common than DM1, is caused by a CCTG expansion within a complex repeat motif within 
intron 1 of the CCHC-type zinc finger, nucleic acid binding protein (CNBP) (ZNF9) on 
chromosome 3q21 [18]. The complexity in some inherited diseases is highlighted by mutations 
in Lamin A/C (LMNA) that can give rise to nine clinically distinct disorders, including atypical 
Werner’s syndrome (OMIM#277700); cardiomyopathy, dilated, 1A (OMIM#115200); 
Emery–Dreifuss muscular dystrophy 2 (OMIM#181350); Emery–Dreifuss muscular dystrophy 
3 (OMIM#616516); Hutchinson–Gilford progeria syndrome (OMIM#176670); lipodystrophy, 
familial partial 2 (OMIM#151660); muscular dystrophy, congenital (OMIM#613205); 
muscular dystrophy, limb-girdle, type 1B (OMIM#159001); restrictive dermopathy, lethal 
(OMIM#275210), with either autosomal dominant or recessive modes of inheritance, 
depending upon the nature and position of the mutation [19]. The muscle weakness patterns of 
some MD conditions are shown in Figure 2.2. 
 
 
Figure 2.2 Distribution patterns of muscle weakness in muscular dystrophies. (A) 
Duchenne and Becker muscular dystrophy; (B) Emery-Dreifuss muscular dystrophy; (C) Limb 
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girdle muscular dystrophy; (D) Facioscapulohumeral muscular dystrophy. Grey shading 
represents represents affected areas. Adapted from Mercuri E and Muntoni F, 2013 [13]. 
 
2.2 Current treatment options for muscular dystrophies 
Indeed, with so many different genes involved, modes of inheritance and mechanisms of 
pathogenesis, a common treatment seems highly improbable. The “gold standard” drugs 
available to treat some of the MDs, and in particular DMD, are the corticosteroids 
“prednisone/prednisolone” and “deflazacort,” but the benefits for most patients are somewhat 
transient and are accompanied by significant side effects [20]. Although steroids cause weight 
gain, bone demineralization, vertebral compression fractures, hypertension and/or behavior 
disorders, this is still considered the front-line treatment for DMD [21]. 
Gene and/or cell replacement may be considered as logical treatment strategies for many 
forms of MDs, especially those conditions where there is an insufficiency of a particular gene 
product [22], but such approaches are unlikely to be applicable to autosomal dominant 
conditions. Furthermore, viral vector gene replacement is particularly challenging for DMD, 
as the size of the gene transcript and the protein-coding region for the full-length 427 kDa 
muscle-specific isoform are beyond the capacity of viral vectors [23]. Recent advances in 
vector design have seen promising preclinical results with mini-dystrophin and micro-
dystrophin cassettes introduced in utero with adeno-associated virus (AAV) 8 and translational 
optimized AAV (AAV2.5) vector [24,25]. Nevertheless, the widespread and sustained 
expression needed to treat a chronic condition such as DMD still poses challenges [23]. 
 
3. Antisense approaches to treat muscular dystrophies 
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The MDs are caused by mutations in numerous different genes that may have dominant or 
recessive modes of inheritance, influencing many different pathogenic pathways. This allows 
rational therapies to be developed, and depending upon the nature of the gene and gene lesion, 
antisense strategies could be employed to address different types of MDs. 
 
3.1 AO-mediated changes in gene expression 
3.1.1 Suppression of a dominant negative regulator of muscle growth 
Muscle growth is regulated by two major signaling pathways: the insulin-like growth factor 1 
(IGF1) pathway controls muscle protein synthesis (positive regulator pathway) and the 
myostatin–SMAD family member 3 pathway promotes muscle protein degradation (negative 
regulator pathway) [14]. While the muscle growth enhancement modulated by the IGF1 
pathway is more complex, suppressing the myostatin pathway is one potential treatment 
strategy for a number of diseases characterized by muscle wasting, such as inherited MD and 
age- or cancer-induced cachexia. 
Kang et al. reported the use of modified AOs to manipulate myostatin pre-mRNA splicing 
and inhibit myostatin expression, and found that both 2ʹ-OMePS AOs and PMOs yielded 
efficient in vitro and in vivo exon-skipping [27]. Malerba et al. later demonstrated that a PMO 
conjugating to an octaguanidine dendrimer (called Vivo-PMO) is a promising strategy for 
modulating myostatin splicing and reduces myostatin protein production by the induction of 
an out-of-frame transcript as a form of nonproductive splicing [28]. Roberts et al. then 
described the use of siRNA to inhibit myostatin by targeting the promoter-associated RNA 
transcript through the transcriptional gene silencing pathway in mammalian cells [29]. Four 
siRNA sequences were screened to achieve a mean knockdown level of 48% in transfected 
differentiated C2C12 myotubes. 
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Other “indirect target” genes for downregulation that may reduce disease severity in 
several inherited muscle disorders are those involved in fibrosis. Wang et al. described the use 
of 20-nucleotide DNA gapmers, fully phosphorothioated, with five 2′-MOE-modified sugar 
residues on each end to knockdown Kirsten rat sarcoma viral oncogene homolog (Kras) in a 
Wistar rat model, that is involved in tubulointerstitial fibrosis [30]. The results showed that the 
AOs can effectively reduce the level of Kras expression up to 69%, compared to the scrambled 
oligomer control in vitro. The AOs were then subcutaneously administered at a dose of 
12.5 mg/kg to adult male Wistar rats for 6 days, leading to the knockdown of up to 66% 
of Kras mRNA expression levels [30]. Recently, Kemaladewi and colleagues also 
demonstrated that AOs can induce exon-skipping in the mouse TGF-β type I 
receptor Tgfbr1 (Alk5) transcript, one component of the TGF-β signaling cascade that is known 
to stimulate fibrosis and inhibit muscle regeneration in DMD [31]. Briefly, this research group 
designed 21-mer 2ʹ-OMePS AOs targeting exon 2 and 6 of the Tgfbr1 transcript. The results 
showed up to 70% reduction in Tgfbr1 expression in C2C12 transfected cells (compared to 
control AOs) and exon 2 and 6 were confirmed to have been excluded. The AO targeting exon 
2 was found to be more effective in disrupting Tgfbr1 expression, and after intramuscular 
injection into 5-week-old mice over 4 consecutive days (40 µg/day), there was a 50% decrease 
in the levels of the full-length Tgfbr1 transcript [31]. 
 
3.1.2 Limb-girdle muscular dystrophy 
LGMDs, as the name indicates, are a group of inherited neuromuscular disorders characterized 
by muscle weakness and wasting, predominantly affecting the proximal muscles, specifically 
the muscles of the shoulders, upper arms, pelvic area and thighs [15,22], while lower legs and 
feet, lower arms and hands are somewhat less affected [15]. Depending on the gene mutation, 
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LGMD can be transmitted as autosomal dominant (LGMD1) or autosomal recessive (LGMD2) 
traits, with 7–8 subtypes of LGMD1 and 23 subtypes of LGMD2 [32] categorised to date 
(http://www.musclegenetable.fr). There are no treatments available for the dominant LGDM 
conditions, but recent advances in molecular therapy have opened new avenues for targeted 
treatments, in particular, specific downregulation of mutant alleles. 
Recently, Scharner and colleagues showed the feasibility of AO-mediated skipping 
of LMNA exon 5 in human cells [33] as a treatment for selected mutations that cause LGMD1B, 
as the loss of LMNA exon 5 did not compromise gene function. The authors reported that a 20-
mer 2ʹ-OMePS AO can effectively skip LMNA exon 5 in HeLa cells and primary normal human 
dermal fibroblasts [33]. This offers a new approach for therapeutic exon-skipping targeting 
missense mutations, not only for LGMD1B but also for other diseases caused by “gain of 
function” missense mutations in potentially dispensable in-frame exons. 
Barthélémy et al. reported the use of AOs to skip exon 32 in the dysferlin (DYSF) gene 
transcript (OMIM# 603009) to restore function in dysferlin-deficient LGMD2B patient 
myoblast cells carrying a mutation in that exon [34]. The 2ʹ-OMePS AO targeting the splice 
donor site of exon 32 was transfected into myoblasts at 800 nM concentration using 
oligofectamine. Exon-skipping was induced with the appearance of low levels of a dysferlin 
protein missing the 26 residues encoded by that exon. This exon 32 deleted dysferlin isoform 
retained some function as assessed by reduced susceptibility to osmotic shock compared to 
mock-transfected cells (only oligofectamine) (85.2%) or dysferlin patient cells treated with 
nonspecific AO [34]. 
Gao et al. also provided evidence that exon-skipping can be applied to treat some 
LGMD2C patients with selected mutations in Sarcoglycan Gamma (SGCG), the gene encoding 
γ-sarcoglycan [35]. The primary fibroblasts, obtained from LGMC2C patients (exon 6 
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deletion), were induced into a myogenic lineage using a tamoxifen-inducible (Tam-inducible) 
MyoD-expressing construct, and transfected with either single 2ʹ-OMePS AOs (100 nM each) 
or as a cocktail of AOs targeting SGCG exons 4, 5 and 7 (300 nM in total). Dose-dependent 
skipping was induced with the detection of an internally truncated transcript missing exons 4–
7. These authors showed an SGCG isoform missing these exons provided functional benefits 
in a drosophila model, and while more work is needed to confirm applicability in LGMD2C, 
this work highlights the potential diversity of mutations and targets that may respond to AO-
induced splice switching [35]. 
 
3.1.3 Facioscapulohumeral muscular dystrophy 
FSHD is an autosomal dominant MD, with a still somewhat controversial pathogenesis. 
Symptoms are usually characterized as progressive muscle weakness [36] including facial, 
scapular and humeral muscles at the early stage, and abdominal muscles and the musculature 
of the lower limbs and feet as the disease progresses [36,37]. Two types of FSHDs have been 
described, named FSHD1 and FSHD2; these conditions cannot be distinguished clinically but 
are characterized by different genetic origins [38]. Approximately 95% of patients with FSHD 
have FSHD1 that is caused by contraction of a polymorphic repeat structure within the 
subtelomeric region of 4q (4q35), designated D4Z4 [17]. The structure consists of a 3.3–kb 
repeated element: normal alleles have a length of 11–100 repeats, while FSHD patients have 
an array of 1–10 units [15]. Located inside the DZ4Z repeats is double homeobox 4 (DUX4), 
encoding the transcription factor DUX4, which is inappropriately expressed 
upon D4Z4 contraction [39]. In 2002, van Geel et al. reported a polymorphic locus directly 
distal to D4Z4, designated 4qA and 4qB alleles [40], and it was subsequently noted that 
37 
 
contractions of D4Z4 on the 4qB allele do not induce FSHD, although both allelic variants are 
almost equally represented in the population [40]. 
Other genes have been reported to be upregulated in FSHD, including paired like 
homeodomain 1 (PITX1), FSHD region gene 1 (FRG1) and solute carrier family 25 member 4 
(SLC25A4) [41], and these offer targets for AO intervention to downregulate their expression 
by degrading the transcript or inhibiting translation. Exon-skipping 2ʹ-OMePS AOs designed 
to target DUX4 mRNA were reported to downregulate the DUX4 transcript and 
prevent DUX4 protein expression [22]. In 2011, Vanderplanck and colleagues compared two 
mechanisms of suppression: siRNA sequences to silence the transcript and 2ʹ-OMe AOs to 
disrupt normal splicing to downregulate the DUX4 transcript in FSHD primary myotubes in 
vitro [42]. The siRNAs were designed to target motifs unique to DUX4 mRNA, and not 
conserved in the highly similar DUX4c mRNA, whereas the 25–30-mer 2ʹ-OMePS AOs 
targeted the acceptor splice sites of pLAM exons 2 and 3 found distal to the last D4Z4 unit, 
which is involved in pre-mRNA splicing. The DUX4 downstream target, ATROGIN-1, a 
muscle-specific E3 ubiquitin ligase typically activated in FSHD was reduced to a level of 80% 
in siRNA-treated cells, and up to 50% by a splice-switching 2ʹ-OMePS AOs directed 
at pLAM exon 3 in treated cells, compared to untreated FSHD1 myogenic cells [42]. PITX1 is 
a member of the paired family of homeodomain transcription factors, which can be activated 
by DUX4, and was found to be upregulated in patients with FSHD, suggesting 
that PITX1 upregulation may play an important role in FSHD pathogenesis [43]. Pandey et al. 
evaluated two 25-mer PMOs targeting the first 25 bases from the translation start site of 
the PITX1 human transgene, one being a vivo-morpholino as described above, and the other an 
unmodified PMO of the same sequence. PITX1 overexpressing transgenic mice were 
intravenously injected with the vivo-morpholino and the PMO at 10 and 100 mg/kg, 
respectively, once a week for 6 weeks. The mice treated with the vivo-morpholino showed a 
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significant improvement in muscle function, with a 70% reduction in PITX1expression, 
compared to the PBS-treated mice. Analysis of the muscle also showed a 44% (p < 0.05) 
reduction of angular-shaped atrophic fibers in mice treated with the vivo-morpholino, 
compared to the PBS-treated control, while the mice treated with the unconjugated PMO did 
not show any significant improvement [43]. 
 
3.1.4 Myotonic dystrophy 
Myotonic dystrophy (DM) is a chronic autosomal-dominant disease characterized by 
progressive muscle atrophy, defects in heart conduction and myotonia. DM is classified into 
type 1 (DM1) and type 2 (DM2) based on their molecular pathology, with DM1 caused by the 
expansion of CTG repeats in the 3′ UTR of DMPK while in DM2, the cause is a CCTG 
expansion in intron 1 of CBNP (ZNF9) [18]. In both cases, the expansion is outside the protein-
coding region and the pathogenic basis is the toxic effect of the mRNA carrying the CUG or 
CCUG expansion [18]. Hence, rational therapeutic strategies would be the following: AO-
induced degradation of toxic RNA and inhibition of the pathogenic interaction of toxic RNA 
with nuclear proteins, such as muscleblind-like. In 1996, Galderisi et al. reported a 75% 
reduction in DPMK mRNA levels in HepG2 and K562 cell lines treated with 
phosphorothioated DNA AOs [45]. Using the RNase-H pathway, these AOs targeted the first 
exon of DMPK mRNA, and showed an effect 6 hours after transfection, but after 24 hours, the 
level of DPMK mRNA returned to normal because of the relatively short half-life of PS 
molecules [45]. 
Bhagavati et al. showed a 76% decrease in the level of myotonin protein in myoblasts 
transfected with a C5 propyne-pyrimidine-modified PS AOs targeted to the translation 
initiation site of DMPK [46] and observed that a large percentage (about 48 – 90%) of AO-
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treated myoblasts underwent apoptosis within 24 hours. Using a fully 2ʹ-OMe PS-modified 
(CAG)7 AO, Mulders et al. described silencing of the mutant DMPK RNA in a novel DM500 
myotube in vitro model [47]. Direct administration of this AO into the muscle of a DM1 mouse 
model showed a significant reduction in toxic (CUG)n RNA levels and a normalizing effect on 
aberrant pre-mRNA splicing. In 2009, Wheeler et al. reported a 25-mer morpholino oligomer, 
CAG25, designed to target the CUG expansion repeat and alter the conformation of the 
expanded triplet repeat [48]. In vitro results showed that the CAG25 morpholino oligomer was 
able to form a stable heteroduplex with the targeted RNA containing CUG repeats, although 
significant reduction in the toxic RNA level was not achieved. CAG25 was also studied in 
vivo using transgenic mice with the disease [48]. 
In 2011, Lee et al. designed gapmer AOs containing CAG sequences with 3–4 LNA or 2ʹ-
MOE nucleotides on the flanking ends and 8–10 PS nucleotides in the central region, to reduce 
expanded CUG transcripts and RNA foci in the COSM6 cell line and EpA960/HSA-Cre mouse 
models of DM1, by RNase-H activation [49]. The results indicated that the best AOs from their 
library can reduce toxic mRNA level in vitro by up to 70%, but additional optimization was 
needed for better effects in vivo. Recently, Wojtkowiak-Szlachcic et al. showed that very short 
all-LNA-modified AOs (8–10-mer) can effectively bind the CUG repeat in the transcript and 
block interaction between the toxic CUG expansion and muscleblind-like protein in vitro [50]. 
For in vivo analysis, the homozygous HSALR transgenic mouse model was used and LNA-
modified AOs were delivered by intramuscular injection, followed by electroporation. The 
results indicated that LNA is stable in the cellular environment and have potential as a therapy, 
as beneficial effects can be achieved after 20 days with PO-LNA-CAG-10 (the lead LNA) in 
vitro and by 14 days in the differentiated muscle fibers of HSALR mice in vivo [50]. Recently, 
the ISIS Pharmaceuticals (Carlsbad, CA, USA) drug candidate for DM1, called IONIS-DMPK-
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2.5Rx has completed phase I/II clinical trials with mixed results (https://us8.campaign-
archive.com/?e=[UNIQID]&u=8f5969cac3271759ce78c8354&id=8cc67ae9b8). 
 
3.1.5 Congenital muscular dystrophies 
The congenital muscular dystrophies (CMDs) are a group of rare MDs, in which symptoms 
may present at birth or in infancy, including progressive muscle weakness and dystrophic 
pattern on muscle biopsy [51,52]. To date, there is no treatment available for these conditions, 
but as pathogenic and disease mechanisms are revealed, rational therapies can be designed. In 
2013, Aoki et al. demonstrated that exon skipping could be utilized to rescue one CMD mice 
model of Lama2 deficiency [53]. Aoki and colleagues transfected PMOs targeting either exonic 
sequences or exon–intron junctions of the murine Lama2 exon 4 into dy3K/dy3K mice 
fibroblasts, derived from an animal model of laminin-α2 chain-deficient CMD that shows 
severe dystrophic change with active muscle regeneration. Their results showed that mutated 
exon 4 was successfully skipped and 20% of the fiber membranes were expressing detectable 
laminin-α2; more importantly, there was an increase in the life span of the treated mice [53]. 
Fukuyama congenital muscular dystrophy, another form of CMD [51], arises from an 
insertion of the SINE-VNTR-Alu (SVA) retrotransposon into the 3′ UTR of the fukutin gene 
[54]. Taniguchi-Ikeda et al. reported that the aberrant mRNA splicing could be the molecular 
pathogenesis of Fukuyama congenital muscular dystrophy. PMO 25mers were designed to 
target potential splice-modulating sequences of SVA-inserted fukutin, including a splicing 
acceptor site, a splicing donor site, exonic splicing enhancers and intronic splicing enhancers. 
These compounds were injected into a knock-in mouse model carrying a humanized fukutin 
exon 10, where there was induction of up to 50% normal fukutin mRNA, and expression of the 




3.2 AO-mediated exon-skipping as a therapy for Duchenne muscular dystrophy 
Clearly, there are many pathogenic mechanisms that can lead to one of the MDs, and different 
strategies, using appropriate AO chemistries, have therapeutic potential for some of these 
conditions. AOs can be used to block toxic RNA sequences or downregulate gene expression 
through induction of RNase-H cleavage or RNA silencing, or to alter gene expression by 
modulating splicing. Of all the AO applications relevant to neuromuscular conditions, the most 
clinically advanced is the use of splice switching AOs to reframe the dystrophin mRNA, 
disrupted by DMD exonic deletions. DMD arises from protein-truncating mutations, most 
commonly, frame-shifting deletions of one or more exons in DMD, ablating functional 
dystrophin expression [55]. Missense mutations have been reported, but are uncommon, and 
other DMD lesions that compromise functional expression include exon duplications, intra-
exonic indels, nonsense mutations and changes that disrupt normal splicing. While boys 
diagnosed with DMD typically lose independent ambulation by the age of 12 years [56], those 
diagnosed with Becker muscular dystrophy (BMD) remain ambulant until at least the age of 
16 years. BMD also arises from DMD mutations, but these gene lesions are generally in-frame 
deletions that allow synthesis of an internally truncated dystrophin isoform retaining some 
function. Depending upon the nature and location of these in-frame deletions, BMD individuals 
present with a spectrum of severity: from asymptomatic to loss of ambulation after the age of 
16 years [57]. In some cases, a diagnosis of MD may be made serendipitously or late in life 
[58]. 
There are several DMD features that permit splicing intervention as a therapeutic strategy, 
once efficient splice-modifying parameters have been identified. DMD, located on the short 
arm of X-chromosome, is the largest gene known, containing 79 exons spanning 2300 kB, and 
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as such undergoes extensive splicing. The predominant muscle-specific mRNA isoform is 
approximately 14 kB in length and is translated into the 427 kDa isoforms of 3685 amino acids 
[55]. Three promoters drive the full-length isoforms expressed in skeletal, smooth and cardiac 
muscle, and the central nervous system, as well as four promoters within introns 29, 44, 55 and 
62 that direct the synthesis of shorter isoforms expressed in other tissues. The applicability of 
AO-mediated splice intervention has been widely explored in DMD, and includes various 
chemically modified AOs. Several research groups explored different AO chemistries as 
splice-switching agents to alter DMD pre-mRNA processing, and it is now evident that several 
types of compounds could be used to induce exon skipping in vitro and in vivo. However, clear 
differences in the efficacy of compounds are evident, with some AOs inducing exon skipping 
at concentrations in vitro that would not be practical when translated to the clinic. 
Takeshima et al. first reported the use of a 2ʹ-OMe-modified AO to modulate dystrophin 
pre-mRNA splicing in an in vitro expression system using Hela cell nuclear extracts and a 
partial dystrophin gene sequence construct [59]. An AO was designed to target the first 31 
nucleotides of an intra-exonic region of exon 19, found to be deleted in a DMD patient. 
Subsequently, Pramono et al. reported DMD exon 19 skipping after the transfection of human 
lymphoblastoid cells with a DNA AO of the same sequence [60]. In both these cases, the AOs 
did not have a PS backbone, but were sufficiently stable to induce some degree of exon 19 
skipping in vitro, at least when transfected into cells at relatively high concentrations. 
Although DNA AOs are typically used to induce mRNA degradation through RNase-H 
activation, Pramono and colleagues reported a DNA AO as a splice-switching oligomer. While 
convention suggests this could have induced RNase-H degradation of the dystrophin transcript, 
it is clear that not all DNA AOs can induce efficient RNase-H degradation. Nevertheless, the 
unequivocal demonstration of the induced transcript suggests that exon 19 skipping occurred 
within the nucleus and the resultant exon 19-deleted transcripts would not be susceptible to 
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RNase-H degradation [60]. In 2001, Takeshima et al. again showed the efficacy of their 31-
mer deoxy-PS AO to induce exon 19 skipping in muscle cells derived from a DMD patient 
[51]. Gebski et al. replicated exon 19 skipping in immortalized murine myogenic cells after 
transfection with a DNA oligonucleotide (on a PS backbone), but the exon 19 skipping was 
inefficient, less than 5% of that compared to the same sequence prepared as a 2ʹ-OMe AOs on 
a PS backbone [62]. Clearly, some AO chemistries are more efficient at inducing splice 
switching than others, and it is important to identify those compounds most likely to be 
applicable in the clinic. The 2ʹ-OMePS AOs were clearly more efficient than DNA or peptide 
nucleic acid (PNA), at least when delivered into cells as cationic lipoplexes. 
Aartsma-Rus et al. evaluated the ability of several different AO chemistries, including 2ʹ-
OMe, LNA, PMO and PNA, to induce exon 46 skipping in vitro in primary human myoblasts 
from a DMD patient carrying a deletion of exon 45 [63]. Using their optimal 2ʹ-OMePS AO 
targeting DMD exon 46 as a positive control, they showed that the LNA yielded the highest 
skipping efficiency, 85% relative to the positive control level of 20%, while the PMO showed 
only 5–6% exon 46 skipping and the PNA was found to be ineffective. PNA was also found to 
be ineffective in inducing exon-skipping [64], but now consider this was attributable to the 
maximum length of the PNA that could be synthesized at the time. Aartsma-Rus et al. used a 
PNA of only 14 bases [63], and evaluated a 14-mer and a 16-mer, all tagged with four lysines 
to facilitate uptake. Recently, Shimo et al. investigated the scope of LNA nucleotides in exon 
skipping as mixmer AO constructs [65]. A series of LNA-modified splice-switching 
oligonucleotides containing around five to eight LNA units in each sequence was produced to 
target DMD exon 58, and the LNA-modified splice-switching oligonucleotides demonstrated 
very efficient exon skipping. It is noteworthy that the number of LNA in the sequence and the 
melting temperature of the AOs are important factors that contribute to the overall efficacy and 
specificity of exon skipping, and in this experiment, the lowest optimal length for inducing 
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exon skipping was a 13mer with six LNA nucleotides [65]. Yin et al. were able to source a 20-
mer PNA targeting the same donor splice site of Dmd exon 23 and demonstrated modest exon 
skipping in vitro [66]. However, in vivo experiments using intramuscular injection of PNA into 
2-month-old mdx mice with a single dose of 5 μg PNA into the tibialis anterior muscle did 
demonstrate significant increases in dystrophin-positive muscle fibers after 2 weeks, compared 
to age-matched control mdx mice. 
In 1999, Wilton et al. demonstrated specific skipping of exon 23 in myoblasts 
from mdx mice, after transfection of 2ʹ-OMePS AOs targeting the Dmd exon 23 donor splice 
site [67]. In this study, AOs were designed to target either the 3ʹ (acceptor) and 5ʹ (donor) splice 
sites of exon 23 in the dystrophin gene transcript (Figure 2.3). Only the AO targeting the donor 
splice site was found to induce specific exon-23 skipping in a dose-dependent manner. In 
2001, Dmd exon-23 skipping was further optimized in vitro in H-2Kb-tsA58 mdx myoblasts 
using 2ʹ-OMePS AOs, and then demonstrated in vivo by intramuscular injections of the same 
AO into mdx mice [68]. Mann et al. later improved the design of the AO targeting Dmd exon 
23 in mdx mice and achieved higher efficiency at lower doses [69]. 
 
 
Figure 2.3 Schematic illustration of the AO binding site at the exon 23-intron 23 junction 




Subsequently, Wilton and colleagues synthesised PMO AOs using the same sequence 
previously reported [67], and evaluated as splice-switching compounds in which poor uptake 
of the uncomplexed oligomers in vitro was identified as the contributing factor to the low exon-
skipping efficiency. It should be noted that the 2ʹ-OMe AOs are not efficiently taken up in 
vitro unless complexed with a delivery agent, such as a cationic liposome preparation or 
polyethyleneimine. In order to compare PMO exon-skipping potential under comparable 
transfection conditions, leashes (DNA or RNA oligonucleotides complementary to the PMO) 
were used to allow lipoplex formation with cationic liposomes for improved uptake through 
the cell membrane [70]. Once the PMO delivery limitation was addressed in vitro, efficient 
exon skipping was induced in vitro and in vivo. Dmd exon-23 skipping in mdx mice was 
induced at high efficiency using a PMO targeting the exon 23 donor splice site, with and 
without leash and cationic liposomes. Dystrophin was detected at the sarcolemma of muscle 
fibers for 2 weeks after injection of the PMO [70]. Heemskerk et al. reported the in 
vivo comparison between 2′-OMePS and PMO chemistries for dystrophin exon-skipping, and 
showed that the 2ʹ-OMePS (17–25-mer) and PMO (25-mer) AOs induced skipping of mouse 
exon 23 in vivo by intravenous injection and DMD exons 44, 45, 46 and 51 in the 
humanized (h)DMD mice by intramuscular injection [71]. The PMO AOs induced higher 
levels of exon-23 skipping and dystrophin expression in mdx mouse muscle than that induced 
by the same sequence as a 2ʹ-OMePS AO after injection thrice a week for 3 weeks at high dose 
(14.52 µmol/kg or 100 mg/kg). For DMD exon 44, no significant difference in exon-skipping 
between the 2ʹ-OMePS and PMO compounds was observed, whereas for exon 45, 46 and 51, 
the PMO performed better than the 2ʹ-OMePS, after the mice were injected for 2 consecutive 
days with 2.9 nmol of AOs (approximately 20 µg) in 50 µl physiologic saline [71]. 
In 2005, Lu et al. demonstrated the systemic delivery of 2ʹ-OMePS AO 
targeting Dmd exon 23 in mdx mice [72]. The AO (2 mg) was dissolved in 200 µl of saline 
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with pluronic F127 at a final concentration of 250 µg/ml and administered intravenously 
through tail vein injection into mdx mice at 6 weeks of age three times a week. Dystrophin 
expression was confirmed body wide, but not in cardiac muscles [72]. Later, Fletcher et al. 
reported localised and systemic delivery of 2ʹ-OMePS, PNA and morpholino AOs 
targeting Dmd exon 23 in mdx mice [64]. The study compared the dystrophin expression levels 
between three treatments and concluded that PMO was the most effective, with longer duration 
of effect and higher dystrophin expression. Alter et al. also investigated the systemic utility of 
the PMO injected into the tail vein of a 6-week-old mdx mouse and showed increased 
dystrophin expression at various doses [73]. Experiments were also conducted in the golden 
retriever muscular dystrophy (GRMD) dog model using AOs designed to skip exons 6 and 8. 
McClorey et al. reported that with the removal of exon 6 and 8, the dystrophin reading frame 
is restored in this canine model in vitro [74]. Yokota et al. reported AO-mediated exon skipping 
to address the exon 7 splice site mutation in the GRMD model of DMD, using three PMOs in 
a cocktail targeting exon 6 and 8 to restore the reading frame [75]. The optimised AOs were 
then delivered into GRMD dogs by intravenous delivery and it was reported that in the dog that 
received 200 mg/kg, seven times a week, the AOs successfully induced “body-wide dystrophin 
expression” with an average increase of 26% compared to untreated control, although some 
muscles showed minimal expression of dystrophin [75]. 
Goyenvalle et al. reported an in vivo comparison of antisense nucleic acid analogues 
targeting Dmd exon 23; tcDNA, 2ʹ-OMe PS and PMO. The adult mdx mice were injected 
intravenously with dosages of up to 200 mg/kg/week for 12 weeks. The tcDNA treatment was 
reported to achieve up to five to six folds higher levels of exon 23 skipping in several muscles 
than the 2′-OMePS and PMO compounds [76]. Jirka et al. evaluated the potential of 2ʹ-Fluoro 
(2’-F) AOs on a phosphorothioate backbone targeting different human and mouse dystrophin 
exons in vitro and in vivo [77]. The authors explained that 2ʹ-FPS AOs showed higher exon 
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skipping levels compared to 2ʹ-OMePS in vitro. However, a 2ʹ-FPS AO targeted Dmd exon 23 
was ineffective in mdx mice after intramuscular administration (twice, at 2.9 nmol) and after 
8 weeks of systemic treatment (four injections of 50 mg/kg/week). The authors are currently 
evaluating whether the effect is specific only to Dmd exon 23 [77]. 
 
3.3 Clinical trials 
Two oligonucleotide chemistries capable of inducing dystrophin exon-skipping have been 
reported and two parallel clinical trials were initiated to evaluate DMD exon-51 skipping, as 
efficient removal of this exon would reframe the message in the largest subgroup of DMD 
patients. The Dutch firm Prosensa Therapeutics B.V. (Leiden, Netherlands; now acquired by 
BioMarin Pharmaceuticals Novarto, CA, USA) investigated dystrophin exon-51 skipping 
using Drisapersen-a 2ʹ-OMePS AO; while Sarepta Therapeutics (Cambridge, MA, USA 
formerly AVI Biopharma) utilised the PMO chemistry (Exondys 51 or Eteplirsen) to achieve 
the same goal. Both trials followed similar formats: demonstration of dystrophin expression 
after an intramuscular injection [78,79] and then analysis of pre- and post-treatment biopsies 
to demonstrate an increase in dystrophin expression and correct localisation. As anticipated 
from pre-clinical animal studies [80], these studies demonstrated dystrophin expression 
localised around the injection site, which was important in showing proof of concept, and also 
showed no overt harmful effects. Both drugs have entered Phase III clinical trial, in which 
Drisapersen was evaluated in a trial sponsored by GlaxoSmithKline (Brentford, UK) that was 
halted in November 2013 because primary and secondary end points were not met. A detailed 
analysis of this study has been published by Voit et al. [81]. The failure to meet the end points 
cannot be regarded as surprising, since there was no concomitant increase in dystrophin after 
extended treatment with Drisapersen. Despite a publication citing dystrophin expression up to 
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15% of normal level [82], a critical evaluation of this data would suggest there has only been 
a fractional increase in dystrophin levels after exon-skipping treatment [83]. The clinical trial 
data is being further interrogated to ascertain if younger boys may be more responsive to the 
drug. In contrast, Exondys 51 has been given accelerated approval by the US FDA for the 
treatment of DMD in September 2016. Exondys 51 has been shown to produce modest 
increases in dystrophin protein and showed an excellent safety profile in the trial participants. 
Mendell et al. reported results after 48 weeks treatment, and while 10 of the 12 boys maintained 
similar levels of ambulation, there was unequivocal evidence at both the RNA and the protein 
levels that Eteplirsen had altered the defective dystrophin expression in the trial participants 
and allowed synthesis of the expected BMD-like dystrophin [84]. Phase II clinical trials are 
now underway with younger boys aged 4–6 years (NCT02420379) and older boys aged 7–21 
years (NCT02286947).  
Three additional drugs including PRO044 (BMN044), PRO045 (BMN45) and PRO053 
(BMN053) designed to induce DMD exon 44, 45 and 53 skipping, respectively, were halted by 
Biomarin. In contrast, two drug candidates SRP-4045 and SRP-4053 targeting DMD exon 45 
and 53, respectively, from Sarepta Therapeutics is currently recruiting participants for phase 
III studies (NCT02500381). Another PMO drug candidate NS-065/NCNP-01 targeting DMD 
exon 53 from Nippon Shinyaku (Kyoto, Japan)- a Japanese pharmaceutical company- has 
recently completed phase II clinical trial (NCT02740972), and currently recruiting for 
extension study (NCT03167255). In addition, a global Phase I clinical trial (NCT03508947) 
initiated by Wave Life Sciences is currently enrolling patients to evaluate the safety and 




4. Exploring novel chemically-modified nucleic acid analogues towards 
improving therapeutic effect of splice-switching antisense oligonucleotide 
in Duchenne muscular dystrophy 
Induced exon-skipping using splice-switching AOs has been widely explored and validated as 
a viable treatment alternative for DMD [85]. The approval of Exondys 51 (PMO chemistry, 
Sarepta Therapeutics) by the US FDA, and the rejection of Drisapersen (2’-OMePS chemistry, 
Biomarin) highlights the importance of chemically-modified nucleic acid analogues towards 
improving therapeutic effects and limiting possible toxicity of the AOs. Utilising these 
analogues may enhance the AO nuclease stability, target binding affinity and specificity.  
To further validate the scope of using modified nucleic acid analogues in developing 
antisense oligonucleotide-based therapy, different chemically-modified AOs targeting exon 23 
in mouse dystrophin transcript were designed, synthesised and evaluated the exon-skipping 
efficiency utilising a Dmd in vitro model. Briefly, the modified AOs were transfected into 
cultured mouse H-2Kb-tsA58 mdx myotubes, followed by semi-quantitative evaluation of the 
exon-skipping efficacy (RT-PCR and densitometry analysis). In addition, these modified AOs 
were also characterised by their target binding affinity (via melting temperature assay), 
nuclease stability (via enzyme degradation assay) and cytotoxicity (via cell viability assay). 
 
4.1 General experimental procedure using antisense oligonucleotides inducing 
exon-skipping in Dmd transcript 
4.1.1 Design and synthesis of chemically-modified AOs  
AOs were synthesised in-house on either ABI Expedite® 8909 (Applied Biosystems, Foster 
City, California, USA) or ÄKTA Oligopilot Plus 10 (GE Healthcare Life Sciences, Parramatta, 
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NSW, Australia) oligonucleotide synthesis system using standard phosphoramidite chemistry 
at 1 µmol scale.  All synthesis reagents for AKTA and Expedite were purchased from Merck 
Millipore, Bayswater, VIC, Australia, and Sigma-Aldrich, Castle Hill, NSW, Australia, 
respectively. Synthesised oligonucleotides were deprotected and cleaved from the solid support 
by treatment with NH4OH (Merck Millipore) at 55 oC overnight, and the crude oligonucleotides 
were then purified by desalting through illustra NAP-10 Columns (GE Healthcare Life 
Sciences). 
   
4.1.2 Melting temperature analysis of the antisense oligonucleotides 
The samples were prepared as duplexes by mixing equal volume of the AO and the synthetic 
complementary RNA sequence at 2 μM concentration in a buffer solution containing 10 mM 
NaCl, 0.01 mM EDTA adjusted to pH 7.0 by 10 mM sodium phosphate buffer. Before loading 
onto a quartz cuvettes of 1 mm path-length, the duplexes were denatured at 95 °C for 10 
minutes followed by slow cooling down to room temperature. The melting process was 
monitored by Shimadzu UV-1800 Spectrophotometer (Shimadzu, Rydalmere, NSW, 
Australia) with the Peltier temperature controller over the range of 20–90 °C at a ramp rate of 
1.0 °C min−1. Tm values were then determined as the maxima of the first derivative plots of the 
melting curves.  
 
4.1.3 Nuclease stability analysis of the antisense oligonucleotides 
Stability of antisense oligonucleotides against 3′ → 5′ exonuclease degradation was 
investigated using phosphodiesterase I from Crotalus adamanteus venom (Sigma-Aldrich, 
Castle Hill, NSW, Australia). Briefly, 10 μM of the oligonucleotides were incubated with 0.08 
units per ml phosphodiesterase in a buffer containing 10 mM Tris–HCl, 100 mM NaCl, and 15 
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mM MgCl2 in a final volume of 60 μl. Samples were incubated at 37 °C and 10 μl samples 
were collected at 0, 10, 30, 60 and 120 minutes and quenched with an equal volume of 80% 
formamide containing bromophenol blue and xylene cyanol gel tracking dyes. The samples 
were then heated for 5 min at 95 °C and analysed by 20% denaturing polyacrylamide gel 
electrophoresis. Quantitation was performed on a Fusion Fx gel documentation system (Vilber 
Lourmat, Marne-la-Vallee, France). 
 
4.1.4 Cell culture and transfection 
H-2Kb-tsA58 mdx myoblasts [86,87] (H2K mdx cells)  were cultured and differentiated as 
described previously [68]. Briefly, when 60–80% confluent, myoblast cultures were treated 
with trypsin (Thermo Fisher Scientific, Scoresby, VIC, Australia) and seeded on 24 well plates 
pre-treated with 50 μg/ml poly-D-lysine (Merck Millipore, Bayswater, VIC, Australia), 
followed by 100 μg/ml Matrigel (Corning, supplied through In Vitro Technologies, Noble Park 
North, VIC, Australia) at a density of 2.5 × 104 cells/well. Cells were differentiated into 
myotubes in Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) 
containing 5% horse serum (Thermo Fisher Scientific) by incubating at 37 °C, 5% CO2 for 24 
hours. Antisense oligonucleotides were complexed with Lipofectin transfection reagent 
(Thermo Fisher Scientific) at the ratio of 2:1 (w:w) (lipofectin:AO) and used in a final 
transfection volume of 500 μl/well in a 24-well plate as per the manufacturer's instructions, 
except that the solution was not removed after 3 hours. For “naked” transfection, the AOs were 
mixed directly with Optimem reduced serum medium and added to the cells. All experiments 
were repeated at least 3 times independently unless specify. 
 




RNA was extracted from transfected cells using Direct-zol™ RNA MiniPrep Plus with TRI 
Reagent® (Zymo Research, supplied through Integrated Sciences, Chatswood, NSW, Australia) 
as per the manufacturer’s instructions. The dystrophin transcripts were then analysed by nested-
RT-PCR using SuperScript™ III Reverse Transcriptase III and AmpliTaq Gold® 360 DNA 
Polymerase (Thermo Fisher Scientific) across exons 20–26 as described previously [68]. The 
amount of RNA used for the primary amplification (55 οC for 30 min, 94 οC for 2 min before 
entering 31 cycles of 94 οC for 30 sec, 55 οC for 30 sec and 68 οC for 90 sec) was 50 ng/µL and 
1 µL of this primary PCR products was subjected to the secondary PCR (94 οC for 6 min before 
entering 33 cycles of 94 οC for 30 sec, 55 οC for 1 min and 72 οC for 2 min). Finally, the 
secondary PCR products were separated on 2% agarose gels in Tris–acetate–EDTA buffer and 
the images were captured on a Fusion Fx gel documentation system (Vilber Lourmat, Marne-
la-Vallee, France). Densitometry was performed by Image J software [88]. The actual exon-
skipping efficiency was determined by expressing the amount of exon-23 skipped RT-PCR 
product as a percentage of total dystrophin transcript products. 
 
4.1.6 Cell viability assay 
Cells were seeded and transfected with the AOs as described previously. After 24 hours, cell 
viability assay was performed using a dye-based colorimetric assay (WST-1 reagent, Sigma-
Aldrich). Briefly, WST-1 solution was added at ratio 1:10 (v/v) per well and incubated for 4 
hours at 37 °C, 5% CO2. The absorbance was then measured with a microplate reader 
(FLUOstar Omega, BMG Labtech, Germany) at 450 nm. The cytotoxicity was evaluated based 
on the measured absorbance in comparison to the UT sample. 
 
4.2 Evaluation of novel chemically-modified splice-switching antisense 
oligonucleotides inducing exon-skipping in Duchenne muscular dystrophy 
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4.2.1 Short locked nucleic acid-modified 2’-OMe AOs  
4.2.1.1 Introduction 
Locked nucleic acid (LNA) is one of the prominent nucleic acid analogues with excellent bio-
physical properties and have attracted extensive interests in development of therapeutics as 
well as diagnostics [89-91]. LNA-modified oligonucleotides show very high binding affinity 
to both DNA and RNA oligonucleotides and increased stability against nuclease degradation 
compared to other chemistries, such as 2’-OMe [92,93]. Introduction of LNA nucleotide 
monomers (Figure 2.4) improves the potency of therapeutic oligonucleotides in vitro and in 
vivo over other nucleic acid chemistries when applied as antisense constructs, siRNAs and anti-
miRs, and are also found to be well tolerated in animals [94-100]. 
 
 
Figure 2.4 Structure representation of 2’-OMe and LNA nucleotide monomers used in 
this study. 
 
First described in 1993 by Dominski and Kole [101], AO-mediated splice modulation of 
pre-mRNA is becoming a well-established therapeutic approach. In 2016, two AO drugs were 
approved by the US FDA for the treatment of DMD (Exondys 51, PMO chemistry) [11] and 
SMA (Nusinersen; 2'-OMOE PS chemistry) [12]. In contrast, the 2’-OMePS-based drug 
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candidate, Drisapersen was rejected due to failure to meet primary or secondary endpoints and 
life-threatening toxicity [102]. Alternative strategies are required to further improve the 
efficacy and limit the toxicity of 2’-OMePS AOs if they are to be used for clinical application.  
One approach to possibly limit toxicity of the 2’-OMePS AOs investigated in previous 
studies [103-107], and to further reduce the costs would be to truncate oligonucleotide length. 
Introduction of LNA nucleotide monomers may accomplish this by relying on properties such 
as high target binding affinity, mismatch recognition capability and increased resistance to 
nuclease degradation. Van Deutekom and colleagues [63] reported the use of LNA-fully 
modified AOs to induce dystrophin exon-46 skipping in DMD patient cells and showed that 
the LNA AOs yielded higher levels of the exon-skipping product, however, the sequence 
specificity was low when tested in mismatch experiments. This is not surprising, as higher 
numbers of LNA nucleotides could increase the possibility of off-target binding, and shorter 
molecules would anneal to off-target sites in the genome/transcriptome. However, it was also 
noted that a short single-stranded 15-mer LNA-modified phosphorothioate antisense 
oligonucleotide targeting the microRNA-122 called ‘Miravirsen’ has advanced to a Phase-2A 
clinical trials. So far, the administration of this short LNA-oligo by subcutaneous injection in 
patients at the highest dose (7 mg/kg) for 4 weeks was found to be safe, while exhibited 
significant decrease in hepatitis C virus RNA [108]. In addition, Obika and co-workers [65] 
also reported the design of a series of LNA-modified AOs targeting DMD transcripts and 
evaluated their efficacy in inducing efficient exon-58 skipping in vitro. The results 
demonstrated that the 13-mer with six LNA modifications achieved the highest exon-skipping 
efficacy, while 7-mer was the minimal length required to induce exon-skipping. 
Since the current PMO chemistry is not compatible with the standard solid-phase 
oligonucleotide synthesis procedures, 2’-OMePS AOs would be suitable to investigate the 
impact of LNA nucleotides to develop shorter exon-skipping AOs. Herein, we reported the 
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systematic truncation of 2’-OMePS-modified AOs using LNA nucleotides by constructing 2’-
OMePS/LNA mixmers and 2’-OMePS/LNA gapmer-like AOs to induce exon-23 skipping in 
the mouse dystrophin gene transcript in vitro.  
 
4.2.1.2 Results 
In this study, we used a previously reported 20-mer 2’-OMe AO on a phosphorothioate (PS) 
backbone designed to induce exon-23 skipping in the mouse dystrophin gene transcript [67]. 
The systematic truncation of the 20-mer 2’-OMePS AO (AO1) was performed by removing 1-
4 nucleotides from both 5’- and 3’-ends simultaneously, and their corresponding LNA-
modified variants were synthesised as mixmers and gapmers to generate 18-mer (AO2-5), 16-
mer (AO6-9), 14-mer (AO10-13) and 12-mer (AO14-17) candidate AOs (Table 2.1). All AOs 
were synthesised in-house on a GE AKTA Oligopilot plus 10 synthesiser at 1 micromol scale 
on a PS backbone. The efficacies of all AOs were evaluated for their ability to induce exon-23 
skipping in H2K mdx mouse myotubes in vitro. For this purpose, H2K mdx mouse myoblasts 
were plated on a 24-well plate, differentiated over 24 hours and transfected with the AOs in 
complex with the cationic lipid, Lipofectin, using 2:1 (w:w) ratio initially at 100, 200, and 400 
nM concentrations, to screen exon-skipping efficiency for all AOs, and later at 12.5, 25, 50 and 
100 nM concentrations for the best performing AOs. The cells were collected after 24 h, RNA 
was isolated and RT-PCR analysis was performed by amplifying across exons 20-26 to 
evaluate the skipping efficiency of the AOs as previously reported [68]. The PCR products 
were then analysed by 2% agarose gel electrophoresis, and densitometry analysis of the gel 
images was performed by Image J software. The actual exon-skipping efficiency was 
determined by expressing the amount of exon-23 skipped RT-PCR product as a percentage of 




Table 2.1 AO names and their sequences used in this study. 
AO no. AO name Sequence, 5’→ 3’ direction 
AO1 DmdE23D (+2-18) GGCCAAACCUCGGCUUACCU 
AO2 DmdE23D (+1-17) GCCAAACCUCGGCUUACC 
AO3 DmdE23D (+1-17) GCCAAAClCTlCGGCTlUACCl 
AO4 DmdE23D (+1-17) GCCAAAClCUCGGCTlUAlCCl 
AO5 DmdE23D (+1-17) GlClCAAACCUCGGCUUAClCl 
AO6 DmdE23D (-1-16) CCAAACCUCGGCUUAC 
AO7 DmdE23D (-1-16) CCAAAClCTlCGGCTlUACl 
AO8 DmdE23D (-1-16) CCAAAClCUCGGClUTlACl 
AO9 DmdE23D (-1-16) ClClAAACCUCGGCUUAlCl 
AO10 DmdE23D (-2-15) CAAACCUCGGCUUA 
AO11 DmdE23D (-2-15) CAAAClCTlCGGCTlUAl 
AO12 DmdE23D (-2-15) CAAAClCTCGGlClUUAl 
AO13 DmdE23D (-2-15) ClAlAACCUCGGCUTlAl 
AO14 DmdE23D (-3-14) AAACCUCGGCUU 
AO15 DmdE23D (-3-14) AAAClCTlCGGClUTl 
AO16 DmdE23D (-3-14) AAAClCUCGGlClUTl 
AO17 DmdE23D (-3-14) AlAlACCUCGGCTlTl 
2’-OMe PS nucleotides are represented in uppercase letters; LNA nucleotide monomers are 
represented in bold underlined letters with superscript ‘l’. 
 
4.2.1.2.1 Evaluation of systematically truncated 2’-OMePS AOs to induce exon-23 
skipping in mdx mouse myotubes in vitro 
First, we tested the potential of the truncated 2’-OMePS AOs including AO2 (18-mer), AO6 
(16-mer), AO10 (14-mer) and AO14 (12-mer) in parallel with the 20-mer control AO1. As 
previously reported [67,68], AO1 showed efficient exon-23 (full-length product size 901 bp) 
skipping in vitro by yielding the deletion product of 688 bp at all concentrations (52% at 100 
nM, 57% at 200 nM, and 65% at 400 nM; Figure 2.5). The 18-mer AO2 with the two-nucleotide 
truncation also showed similar efficacy as the 20-mer control AO1, and induced exon-23 
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skipping levels of 47% at 100 nM, 51% at 200 nM, and 62% at 400 nM. However, a significant 
drop in the amount of 688 bp product was observed after transfection with the 16-mer AO6 
(23% at 100 nM, 30% at 200 nM, and 38% at 400 nM). Notably, the 14-mer AO10 and the 12-
mer AO14 failed to show any skipped product of 688 bp (Figure 2.5).  In all AO transfections 
(all concentrations), an additional product band at 542 bp was also observed on the gel (Figure 
2.5) that corresponds to an out of frame exon-22/23 dual skipping product, in line with previous 
reports.[55,56,103-105] We found a similar trend of increasing amount of 542 bp band at 100 
and 200 nM concentrations (Figure 2.5), and a decrease in yield at 400 nM for AO1, AO2 and 






Figure 2.5 RT-PCR and transcript densitometry analysis (aligned with each AO gel lane) 
of RNA prepared from H2K mdx mouse myotubes transfected with progressively 
truncated 2’-OMePS AOs. AO1 = 20-mer; AO2 = 18-mer; AO6 = 16-mer; AO10 = 14-mer; 
AO14 = 12-mer. Triangles indicate increasing AO concentration (100, 200 and 400 nM). FL 
(full-length) = 901 bp, Δ23 (exon-23 skipped) = 688 bp, Δ22-23 (exons-22+23 skipped) = 542 
bp, UT = untreated, -ve = negative control. Green = exon-23 skipped, blue = exons-22+23 
skipped, grey = full-length. 
 
4.2.1.2.2 Evaluation of systematically truncated LNA/2’-OMePS AO mixmers and 




We evaluated the impact of LNA nucleotides in truncated 2’-OMePS AOs for which three 
different types, two mixmers and one gapmer-like AOs, were designed and synthesised by 
incorporating four LNA nucleotides in each sequence (Table 2.1). We evaluated the dystrophin 
exon-23 skipping efficiencies of truncated LNA/2’-OMePS AOs of sizes: 18-mers (AO3-5), 
16-mers (AO7-9), 14-mers (AO11-13) and 12-mers (AO15-17) in vitro compared to the 
corresponding fully 2’-OMePS AOs (Table 2.1).  
All 18-mer LNA/2’-OMePS AOs, AO3, AO4 (mixmer1 and 2) and AO5 (gapmer-like) 
showed efficient exon-23 skipping at all concentrations, similar to that induced by the fully 2’-
OMePS AO2 (Figure 2.6A). The mixmer construct AO4 induced the highest level of exon-23 
skipping by yielding 66 and 72% of the 688 bp skipped transcript product at 200 and 400 nM 
concentrations, respectively, compared to 54 and 66% exon-skipping efficiency induced by the 
unmodified AO2 (Figure 2.6A). All 18-mer LNA/2’-OMePS AOs also induced the exon-22/23 
deletion product of 542 bp at varying yields (Figure 2.7A), however, the band intensity was 





Figure 2.6 RT-PCR and transcript densitometry analysis (aligned with each AO gel lane) of RNA prepared from H2K mdx mouse 
myotubes transfected with AO candidates. (A) 18-mer AOs; (B) 16-mer AOs; (C) 14-mer AOs; (D) 12-mer AOs. Triangles indicate increasing 
AO concentration (100, 200 and 400 nM); FL (full-length) = 901 bp, Δ23 (exon-23 skipped) = 688 bp, Δ22-23 (exons-22+23 skipped) = 542 bp, 





The exon skipping efficiency of 16-mer LNA/2’-OMePS AO variants, AO7 (mixmer 1), 
AO8 (mixmer 2) and AO9 (gapmer-like) was tested under the same conditions as above in 
parallel with the corresponding fully 2’-OMePS AO6. All LNA-modified truncated AOs 
induced the exon-23 deletion product of 688 bp at all tested concentrations, however, higher 
exon-skipping levels were achieved at 200 and 400 nM (Figure 2.6B). Interestingly, the 
mixmer AO8 yielded a higher percentage of exon-23 skipping (75%) than any of 18-mer 
truncated AOs. In contrast, the exon-skipping efficiency of the control fully 2’-OMePS AO6 
was found to be significantly lower at all concentrations, compared to that of LNA-modified 
AOs (Figure 2.6B).  
The efficacies of 14-mer LNA-modified 2’-OMePS AO candidates (AO11, mixmer 1; 
AO12 mixmer 2; and AO13, gapmer-like) were also evaluated together with the corresponding 
fully 2’-OMePS AO10. The LNA/2'-OMePS 14mer-AOs clearly showed the exon-23 deletion 
product of 688 bp at all concentrations tested, although the highest efficiency was observed at 
400 nM (Figure 2.6C). Efficient exon-23 skipping was observed with the mixmer AO12 at 400 
nM, yielding 66% of the skipped product in line with the 20-mer 2’-OMePS AO1. However, 
the control fully 2’-OMePS AO10 failed to induce exon-23 skipping at all concentrations. All 
LNA-modified 14-mer AOs also showed the exon-22/23 dual skipping product of 542 bp as a 
minor product at all concentrations tested (Figure 2.6C).     
The 12-mer AOs, AO15 (mixmer 1), AO16 (mixmer 2) and AO17 (gapmer-like) also 
induced the exon-23 deletion product of 688 bp, however, the yield was found to be low 
compared to the other longer AOs. The LNA/2’-OMePS mixmer AO16 induced a higher 
percentage of exon-23 skipping at 400 nM (29%; Figure 2.6D) than any of the other 12-mer 
AOs. Not surprisingly, the unmodified 12-mer 2’-OMePS AO14 did not yield any exon-23 




4.2.1.2.3 Exon-skipping efficacy analyses of promising LNA/2’-OMePS AOs candidates 
at lower concentrations  
To further investigate the efficacy of truncated LNA-modified 2’OMePS AOs, we then 
analysed exon-skipping at lower concentrations (12.5, 25, 50 and 100 nM). For this purpose, 
the best performing four LNA/ 2’-OMePS AO candidates for each size (AO4, AO8, AO12 and 
AO16) out of 12 candidates were evaluated along with their corresponding fully 2’-OMePS 
AOs (AO2, AO6, AO10 and AO14). The 18-mer AO4 showed efficient exon-23 skipping at 
25, 50 and 100 nM compared to AO2, for which good skipping was observed at 50 nM and 
above (Figure 2.7A). The 16-mer LNA/2’-OMePS AO8 also showed high exon-23 skipping 
efficacy at 25, 50 nM and 100 nM whereas the control AO6 yielded significantly less exon-23 
skipped product (Figure 2.7B). The 14-mer LNA/ 2’-OMePS AO12 was also induced exon-23 
skipping at 50 and 100 nM concentrations, but the 2’-OMePS AO10 failed to induce any exon-
23 skipping (Figure 2.7C). The 12-mer LNA/2’-OMePS AO16 did not exhibit good skipping 
efficacy, however, the exon-23 skipped product was visible at low levels (up to 20%, Figure 
2.7D), and the control fully 2’OMePS AO14 failed to induce any exon-23 skipping at all tested 
concentrations. Notably, there were also bands detected at 542 bp corresponding to dual exon-
22/23 skipping and this product was observed at low yields in all cases, except for the 14-mer 






Figure 2.7 RT-PCR and transcript densitometry analysis (aligned with each AO gel lane) of RNA prepared from H2K mdx mouse 
myotubes transfected with AO candidates at low concentrations. (A) 18-mer AOs; (B) 16-mer AOs; (C) 14-mer AOs; (D) 12-mer AOs. The 
triangles above the gel image indicate increasing AO concentration (12.5, 25, 50 and 100 nM); FL (full-length) = 901 bp, Δ23 (exon-23 skipped) 





In this study, we explored the ability of LNA nucleotides to fine-tune the performance of 2’-
OMePS AOs by screening systematically-truncated LNA-modified 2’-OMePS mixmers and 
gapmer-like AOs to induce exon-23 skipping in the H2K mdx mouse myotubes in vitro. We 
designed and synthesised systematically truncated series of LNA/2’-OMePS AOs (from 18-
mer to 12-mer) and their corresponding 2’-OMePS sequences by systematically removing 1 
nucleotide each from the 3’- and 5’-ends simultaneously, beginning with a previously reported 
20-mer sequence [67,68] (Table 2.1). Two mixmer-types and one gapmer-like LNA/2’-OMePS 
AOs were synthesised containing four LNA nucleotides in each of the sequences. In one of the 
mixmers, two LNA nucleotides were placed towards the 3’-end and in the middle region; while 
in the second mixmer design, three LNA nucleotides were placed towards the 3’-end and one 
LNA in the middle region. The rational for choosing the LNA positions towards the 3’-end 
would be to protect the AOs from the exonucleases with harsh 3’-5’ activity. Moreover, our 
experience implicated that the AOs may perform better if monomer “C” and “T (or U)” are 
modified with LNA. All gapmer-like designs had two LNA nucleotides positioned 
consecutively at both 3’- and 5’-ends. The efficacy of each AO was first tested in H2K mdx 
mouse myotubes in vitro at 100, 200 and 400 nM concentrations.  
The results demonstrated that the 18-mer AO2 with two nucleotide truncations maintained 
similar efficacy to the 20-mer AO1, however, further truncation of the AO2 sequence by 
additional two nucleotides (AO6) resulted in a significant drop in exon-23 skipping efficiency. 
Truncation of 2’-OMePS AOs clearly affected the efficacy, since the 20-mer AO1 was found 
to be one of the best performing AO (but less efficient than the 25-mer AO) [67] in inducing 
exon-23 skipping in vitro, compared to the truncated variants, while the introduction of LNA 
nucleotides in the truncated 2’-OMePS AOs improved the efficacy of exon-23 skipping. All 
18-mer LNA/2’-OMePS AOs induced exon-23 skipping. Interestingly, one of the mixmers 
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AO4 showed higher skipping efficacy than the 20-mer 2’-OMePS AO1 and this may suggest 
that the positioning of LNA nucleotides could be better towards the 3’-end of the AOs. The 
impact of LNA nucleotide inclusion is very evident when analysing the 16-mer AOs, since all 
LNA/2’-OMePS AO variations induced exon-23 skipping at two-fold higher efficiency 
compared to 2’-OMePS AO.  
The best performing LNA-modified 2’-OMePS AOs of each size identified above, 18-mer 
AO4, 16-mer AO8, 14-mer AO12 and AO16 along with the corresponding unmodified 2’-
OMePS AOs were further evaluated for exon-23 skipping efficacy at lower concentrations. In 
general, the AOs showed a similar trend in skipping efficiencies as discussed for those AOs at 
higher concentrations. The results clearly demonstrated that all LNA/ 2’-OMePS AOs were 
capable of inducing exon-23 skipping at lower concentrations, in a dose dependent manner, 
whereas the exon-23 skipping efficiencies of the 2’-OMePS control AOs were significantly 
lower and proportional to the length of the AOs. The 18-mer, 16-mer and 14-mer 
LNA/2’OMePS AO4, AO8 and AO12 showed higher exon-23 skipping efficacy at 25, 50 and 
100 nM concentrations, in a dose dependent manner, whereas the 12-mer AO16 was not 
effective. Although the unmodified 18-mer 2’-OMePS AO showed similar efficacy as the 
LNA/2’-OMePS variant, further reduction in size to a 16-mer significantly affected the yield 
of exon-23 skipped transcript product. The 14-mer and 12-mer truncated sequences failed to 
induce any skipping, and may suggest that the 2’-OMePS chemistry requires a minimum length 
of 16 nucleotides in order to act as an exon-skipping AO sequence. The RT-PCR product of 
542 bp corresponding to exon-22/23 dual skipping was also observed in all cases, except for 





In conclusion, truncation of AOs could substantially reduce the cost and AO-chemistry 
mediated side-effects. Our results highlight that shorter exon-skipping AOs with high efficacy 
can be constructed using LNA nucleotides, in combination with other chemistries such as 2’-
OMePS AOs. Short LNA-modified 2’-OMePS mixmer AOs were found to be more effective 
in inducing dystrophin exon-23 skipping in vitro at very low doses, compared to the unmodified 
2’-OMePS AOs. We suggest that shorter LNA-modified 2’-OMePS AOs may offer great 
potential in improving efficacy and utility of 2’-OMe AOs for therapeutic applications.  
 
4.2.2 Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and D-
altritol nucleic acid-modified 2′-O-methyl RNA mixmer antisense oligonucleotides  
4.2.2.1 Introduction 
The introduction of chemically-modified monomers is widely used for improving the binding 
affinity, stability against nuclease degradation, and also for limiting the immune-stimulatory 
properties of the AOs. Toward this, Herdewijn and colleagues reported the development of 
anhydrohexitol nucleic acid (HNA) [109], cyclohexenyl nucleic acid (CeNA) [110,111] and 
altritol nucleic acid (ANA) [112] (Figure 2.8). HNA forms stable duplexes with 
complementary DNA and RNA oligonucleotides in a sequence selective manner with a ΔTm of 
+1.3 °C per base pair with DNA and a ΔTm of +3 °C per base pair with RNA [109]. In addition, 
HNA monomers show complete stability towards 3′-exonucleases. CeNA is considered to be a 
DNA mimic with a six-membered cyclohexene ring [110,111]. The introduction of CeNA 
nucleotide into the DNA strand of a DNA/RNA hybrid increases the thermal stability of the 
duplex [110,111], and CeNA-modified oligos are very stable against nuclease degradation 
[111]. ANA is another unique nucleic acid analogue with very high hybridisation affinity for 
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complementary RNA oligonucleotides adopting an A-type duplex similar to natural RNA, and 
is very stable in human serum [112]. 
 
 
Figure 2.8 Structural representations of HNA, CeNA and ANA nucleotide monomers 
used in this study. 
 
There are reports on using tricyclo-DNA (tcDNA) oligomers, lock nucleic acid (LNA), 
peptide nucleic acid (PNA), 2’-deoxy-2’- fluoro (2F) RNA and 2’-O, 4’-C-ethylene-bridged 
nucleic acid (ENA) in the evaluation of DMD exon-skipping efficiency [63,65,76,113-115]. 
Herein, we reported for the first time the synthesis of HNA, CeNA and ANA modified AOs 
for exon-skipping applications. Specifically, we synthesised a variation of the 2′-OMe 
oligonucleotide chemistry and evaluated exon-23 skipping efficacy with different mixmer 
designs including HNA/2′-OMePS, CeNA/2′-OMePS and ANA/2′-OMePS (Table 2.2) in 
vitro. 
 
Table 2.2 AO names, sequences and Tm analysis data used in this study. 
AO names Sequence, 5’- 3’ direction Tm, οC 
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2′-OMePS GGCCAAACCUCGGCUUACCU 59.8 
2′-OMePS-mismatch CGCCUAACGUCGGGUAACCA 39.4 
HNA/ 2′-OMePS GhGCCAhAACChUCGGChUThACCTh 52.4 
CeNA/ 2′-OMePS GcGCCAcAACCcUCGGCcUTcACCTc 59.9 
ANA/ 2′-OMePS GaGCCAaAACCaUCGGCaUTaACCTa 62.9 
2′-OMePS nucleotides are represented in uppercase letters; Mismatched nucleotides are 
represented in bold italic letters; HNA nucleotide monomers are represented in bold letters with 
superscript ‘h’; CeNA nucleotide monomers are represented in bold letters with superscript ‘c’; 
and ANA nucleotide monomers are represented in bold letters with superscript ‘a’. 
Complementary pre-mRNA target 5’-r(AG GUA AGC CGA GGU UUG GCC)-3’. 
 
4.2.2.2 Results  
First, we designed and synthesised three different 20 nucleotide mixmer AOs containing HNA 
(HNA/2′-OMePS), CeNA (CeNA/2′-OMePS) and ANA (ANA/2′-OMePS) on a PS backbone 
based on the control 2′-OMePS AO (Table 2.2), which was previously reported to be the most 
efficient AO inducing Dmd exon 23 skipping in vitro [116]. In addition, one additional 
sequence was synthesized by introducing mismatches at all positions where HNA/CeNA/ANA 
was incorporated to gain more insights into sequence specificity. We analysed the melting 
temperature (Tm) of all synthesised AO sequences to the complementary pre-mRNA target 
(Table 2.2). The ANA/2′-OMePS mixmer AO–RNA duplex was found to be more stable with 
a Tm value of 62.9 °C while the CeNA/2′-OMePS–RNA duplex (59.9 °C) and the fully 
modified 2′-OMePS–RNA duplex (59.8 °C) showed similar stability. The HNA/2′-OMePS–
RNA duplex (52.4 °C) was found to be relatively less stable compared to CeNA and ANA. As 
expected, the mismatched 2′-OMePS–RNA duplex (39.4 °C) was found to be destabilizing, 
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demonstrating the impact of sequence specificity. All five AOs including the control AOs were 
then used for evaluating Dmd exon-23 skipping efficacy in mdx mouse myotubes. Briefly, the 
AOs were transfected into differentiated myotubes in complexation with cationic lipids 
(lipofectin) using a 2:1 (w/w) ratio at 50, 100, 200, 300 and 400 nM concentrations. The cells 
were collected after 24 hours, the RNA was isolated and RT-PCR analysis was performed by 
amplifying across exons 20–26 to evaluate the skipping efficiency of the AOs. 
The results clearly showed that all three candidates HNA, CeNA and ANA modified 2′-
OMePS AOs induced exon-23 (band at 901 bp) skipping at 50–400 nM concentrations by 
yielding the 688 bp deletion product in a dose dependent manner (Figure 2.9B to D). 
Densitometry analysis of the gel images was performed to quantify the actual percentage of 
skipping (Figure 2.9B to D). Specifically, the CeNA/ 2′-OMePS mixmer AO achieved the 
highest percentage of exon-23 skipping product of 688 bp at 400 nM (62%, Figure 2.9C), 
compared to HNA/ 2′-OMePS (53%, Figure 2.9B) and ANA/ 2′-OMePS (44%, Figure 2.9D). 
The skipping efficiency of CeNA/ 2′-OMePS AO and HNA/ 2′-OMePS AO steadily increased 
with an upsurge in concentrations from 50 to 400 nM. However, at lower concentrations from 
50 to 200 nM the skipping efficiencies of both HNA/ 2’-OMePS and CeNA/ 2’-OMePS AOs 
were very similar, showing similar yield of the skipped 688 bp product in the densitometry 
analysis. But, at 300 and 400 nM concentrations, CeNA/ 2’-OMePS clearly showed a higher 
efficacy. In the case of ANA/ 2’-OMePS AO, the exon-23 skipping efficiency was not as 
efficient compared to that of CeNA/ 2’-OMePS and HNA/ 2’-OMePS AOs although it showed 





Figure 2.9 RT-PCR and transcript densitometry analysis (aligned with each AO gel lane) 
of RNA prepared from H2K mdx mouse myotubes transfected with AO candidates. (A) 
Fully-modified 2’-OMePS AO; (B) HNA/ 2’-OMePS mixmer AO; (C) CeNA/ 2’-OMePS 
mixmer AO; (D) ANA/ 2’-OMePS mixmer AO. The triangles above the gel image indicate 
increasing AO concentration (50, 100, 200, 300 and 400 nM); FL (full-length) = 901 bp, Δ23 
(exon-23 skipped) = 688 bp, Δ22-23 (exons-22+23 skipped) = 542 bp, UT = untreated, -ve = 
negative control. Green = exon-23 skipped, blue = exons-22+23 skipped, grey = full-length. 
 
As expected, the 2′-OMePS mismatched AO did not show any skipping of exon-23 with 
no visible band at 688 bp (Figure 2.10), while the control 20-mer 2′-OMePS AO induced 
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efficient exon-23 skipping with a visible 688 bp product band, corresponding to exon-23 
deletion (Figure 2.9A). Densitometry analysis showed that the maximum skipping efficacy was 
observed at 200 nM with approximately 62% of the skipped product (Figure 2.9A); however, 
unlike HNA/ 2′-OMePS and CeNA/ 2′-OMePS AOs, there was no further dose dependent 
increase in the skipped product at 300 and 400 nM concentrations. Notably, all tested AOs also 
showed an additional band at 542 bp believed to be due to the undesired dual exon-22 and 23 
skipping products (Figure 2.9A to D). This product is more evident in the case of the control 
2′-OMePS AO, wherein we observed a steady increase in the band intensity from 8% to 22% 
at 50–400 nM concentrations (Figure 2.9A to D). Interestingly, the 542 bp dual exon-22 and 
23 skipping products were almost half in the case of HNA/ 2′-OMePS (2–12%), CeNA/ 2′-
OMePS (3–15%), and ANA/ 2′-OMePS (4–11%) AOs at 50–400 nM (Figure 2.9B to D). 
 
 
Figure 2.10 RT-PCR analysis of RNA prepared from H2K mdx mouse myotubes 
transfected with 2’-OMePS-mismatch AO showed no exon-skipping. The triangles above 
the gel image indicate increasing AO concentration (50, 100, 200, 300 and 400 nM); FL (full-
length) = 901 bp; UT = untreated, -ve = negative control. 
 
Next, we investigated the cytotoxicity of 2′-OMePS, HNA/ 2′-OMePS, CeNA/ 2′-OMePS 
and ANA/ 2′-OMePS in mdx mouse myoblasts. We performed WST-1 (2-(4-iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium), a dye-based colorimetric cell viability 
74 
 
assay 24 hours after treatment with the AO candidates at 400 nM [117]. The results showed 
that HNA/ 2′-OMePS, CeNA/ 2′-OMePS and ANA/ 2′-OMePS AOs did not show any high 
cytotoxicity in the mdx myoblasts; however, the 2′-OMePS AO was found to be slightly more 
toxic under the given concentration (Figure 2.11).  
 
 
Figure 2.11 In vitro cytotoxicity analysis of H2K mdx cells by WST-1 assay after transfected 
with the AO candidates (at 400 nM) in comparison with the untreated cells. UT: untreated. 
Error bars are displayed in SEM of biological duplicates. 
 
4.2.2.3 Discussions 
In this study, we explored the feasibility of 2’-OMePS AOs incorporated with HNA, CeNA 
and ANA nucleotides for exon-skipping application, in comparison to the control fully 
modified 2’-OMePS AO which has shown to be the most effective in inducing exon-23 
skipping in H2K mdx myotubes [68]. The AOs were designed as mixmer contructs with 6 
modified nucleotides distributed across the sequence (Table 2.2). Firstly, we performed the 
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melting temperature assay to evaluate the binding affinity of the AOs against a synthetic 
complementary RNA sequence. The results revealed the Tm as the following order: ANA/ 2′-
OMePS > CeNA/ 2’-OMePS ≈ fully 2’-OMePS > HNA/ 2’-OMePS > 2’-OMePS-mismatch. 
However, the exon-skipping efficiency did not reflect the same trend as the Tm. At 400 nM 
concentration, the CeNA/ 2’-OMePS AO achieved the highest skipping efficacy (62%), 
compared to fully 2’-OMePS (60%), HNA/ 2’-OMePS (53%) and ANA/ 2′-OMePS (44%). It 
is not surprising as the actual binding between the AOs and pre-mRNA in the cell nucleus may 
differ from that in cell-free scenario due to RNA folding.  
In addition, cell viability assay was also performed to assess the toxicity of the modified 
AOs in vitro. The result highlights that HNA, CeNA and ANA-modified AOs can be given at 
higher doses for efficient exon-skipping that could potentially reduce the toxicity of 2′-OMe-
based AOs. It was also noted that the fully-modified 2’-OMePS control AO can be 
administered at lower doses while yielding efficient exon-skipping. To gain more insight, the 
stability tests of all four AOs was conducted using phosphodiesterase I from Crotalus 
adamanteus venom with very high 3′ → 5′ exonuclease activity. In this study, we observed that 
HNA/ 2′-OMePS, CeNA/ 2′-OMePS and ANA/ 2′-OMePS-modified AOs showed high 
stability to exonuclease degradation, whereas the 2′-OMePS AO was found to be relatively less 
stable demonstrating that HNA, CeNA and ANA-modified AOs could be suitable for 





Figure 2.12 In vitro stability study of the fully 2’-OMePS, HNA/ 2’OMePS, CeNA/ 
2’OMePS and ANA/ 2’-OMePS AOs against phosphodiesterase I from Crotalus 
adamanteus venom. min = minutes. 
 
4.2.2.4 Conclusion 
In summary, we have investigated the potential of HNA, CeNA and ANA-modified 2′-OMe 
mixmer AOs for inducing exon-skipping. So far, 2′-OMePS and PMO-based chemistries have 
been studied extensively. Our results demonstrated that HNA/ 2′-OMePS, CeNA/ 2′-OMePS, 
and ANA/ 2′-OMePS mixmer AOs can effectively induce Dmd exon- 23 skipping in 
vitro while maintaining the cell viability and high stability to nuclease degradation. In addition, 
they also limited the unfavourable dual exon-22/23 skipping in the Dmd gene transcript. Our 
results highlight the importance of exploring various chemically modified AOs in exon-
skipping therapy, and based on the results, we firmly believe that the introduction of modified 
nucleotide monomers such as HNA and CeNA as mixmers with 2′-OMe nucleotides or locked 
nucleic acid (LNA) nucleotide may offer great potential in improving exon-skipping 
therapeutic efficacy [89,90].  
 




AOs composed of natural nucleic acid monomers (DNA or RNA) possess relatively low 
binding affinity to complementary RNA or DNA sequences, while showing poor resistance to 
enzymatic degradation [1]. To overcome this, chemically-modified nucleotide analogues are 
generally introduced to modify the nucleobase, sugar moiety or the internucleotide linkages. 
Twisted intercalating nucleic acid monomer possessing 1-ethynylpyrene moiety in 
the para position of the benzene ring (p-TINA, Figure 2.13) was initially designed to increase 
thermal stability of Hoogsteen-type parallel DNA duplexes and triple helixes [117,118]. Later, 
by changing the position of 1-ethynylpyrene moiety from para to ortho position of the benzene 
ring (o-TINA, Figure 2.13), the thermal stability of Watson–Crick type antiparallel duplex 
helices was significantly improved [119]. o-TINA molecule is now commercially available and 
generally used in constructing primer sequences for PCR amplification. In this study, we have 
evaluated the potential of both p-TINA and o-TINA molecules modified antisense 
oligonucleotides to induce exon-skipping in DMD as a model system.  
 
 
Figure 2.13 Structural representations of para (p)-TINA and ortho (o)-TINA monomers 




4.2.3.2 Results  
First, we have designed and synthesised 20-mer 2′-OMe AO sequences containing o-TINA 
and p-TINA on a phosphorothioate (PS) backbone based on the fully-modified 2′-OMePS AO 
as a positive control targeting DMD exon-23 in mdx mouse myotubes (Table 2.3). Then, we 
analysed the melting temperature (Tm) of the AO sequences using the targeted complementary 
pre-mRNA (Table 2.3). Briefly, 2.0 mM of each strand was mixed in 5 mM sodium phosphate 
buffer, pH 7.0 containing 70 mM NaCl and 0.05 mM disodium EDTA. Thermal stability was 
measured at 260 nm with the temperature ramp of 1.0 οC min-1. Tm values were reported as 
maxima of first derivatives of melting curves with uncertainty of ±0.5 οC as determined by 
repetitive measurements. RNA target is: 5’-r(AG GUA AGC CGA GGU UUG GCC)-3’.  
 
Table 2.3 AO names, sequences and Tm analysis data used in this study. 
AO names Sequence, 5’- 3’ direction Tm, οC 
DNA d(GGCCAAACCTCGGCTTACCT) 65 
RNA r(GGCCAAACCUCGGCUUACCU) 77 
2′-OMePS GGCCAAACCUCGGCUUACCU 79 
1p-TINA/ 2’-OMePS GpGCCAAACCUCGGCUUACCU 74.0 
1o-TINA/ 2’-OMePS GoGCCAAACCUCGGCUUACCU 77.5 
2o-TINA/ 2’-OMePS GoGCCAAACCUCGGCUUACCoU 79 
2′-OMePS nucleotides are represented in italic letters; para-TINA nucleotides are represented 
in bold letters with superscript ‘p’; ortho-TINA nucleotides are represented in bold letters with 
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superscript ‘o’. All 2′-OMe and TINA-modified oligonucleotides possess phosphorothioate 
backbone. 
Thermal stability experiments revealed that the use of p-TINA monomer at the 5′-end of 
the 2′-OMePS sequence led to the slight destabilisation of duplexes. On the other hand, the use 
of two o-TINA monomers (sequence 2o-TINA/ 2′-OMePS) resulted in a slight stabilisation of 
the duplex towards complementary pre-mRNA target.  
We then performed the in vitro stability study of the AOs using phosphodiesterase enzyme 
with very high 3′ → 5′ exonuclease activity. The results clearly indicated that under our 
conditions 2o-TINA/ 2′-OMePS AO was found to be relatively more stable followed by the 2′-
OMePS, 1o-TINA/ 2′-OMePS and 1p-TINA/ 2′-OMePS AOs respectively (Figure 2.14). In 
fact, the results showed the ability of TINA-modified AOs to render high nuclease stability 
when incorporated at the 3′-end of the sequence, whereas all other AOs which don't possess a 




Figure 2.14 In vitro stability study of the AOs against phosphodiesterase I from Crotalus 
adamanteus venom. (A) fully modified 2′-OMePS; (B) 1o-TINA/ 2′-OMePS; (C) 2o-TINA/ 
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2′-OMePS; (D) 1p-TINA/ 2′-OMePS. t: template control without enzyme; all time points are 
in minute. 
 
Next, we tested the feasibility of TINA-modified AOs (1p-TINA/ 2′-OMePS, o-TINA/ 2′-
OMePS and 2o-TINA/ 2′-OMePS) in inducing exon-23 skipping. Briefly, primary mdx mouse 
myoblast was cultured and seeded at 2.5 × 104 cells per well on a 24 well plate and transfected 
with the AOs (Table 2.3) using Lipofectin as a transfection agent. Twenty-four hours after 
transfection, the cells were collected and isolated the RNA, and RT-PCR was performed. The 
products were analysed by 2% agarose gel-electrophoresis. The results clearly showed that the 
TINA-modified oligonucleotides successfully induced exon-23 skipping by showing product 
bands at 688 bp corresponding to exon-23 deletion from the full-length product (901 bp) 





Figure 2.15 RT-PCR and transcript densitometry analysis (aligned with each AO gel 
lane) of RNA prepared from H2K mdx mouse myotubes transfected with DNA, RNA, 
fully 2′-OMePS and TINA-modified AOs. The triangles above the gel image indicate 
increasing AO concentration (100 and 200 nM); FL (full-length) = 901 bp, Δ23 (exon-23 
skipped) = 688 bp, Δ22-23 (exons-22+23 skipped) = 542 bp, UT = untreated, -ve = negative 
control. Green = exon-23 skipped, blue = exons-22+23 skipped, grey = full-length. 
 
However, efficiency of exon-skipping was not as high compared to the fully-modified 2′-
OMePS AO which yielded the skipped product of 688 bp in 61% at 100 nM and 67% at 200 
nM concentrations (Figure 2.15). AO modified with 1p-TINA/ 2′-OMePS showed the skipped 
product in 38% and 42% respectively at 100 and 200 nM concentrations. In the case of 1o-
TINA/2′-OMe-PS mixmer AO, the yield of 688 bp skipped product was 50% at 200 nM 
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although the yield at 100 nM was only 19%. Compared to 1p-TINA/ 2′-OMePS mixmer AO, 
the 1o-TINA/ 2′-OMePS showed superior efficacy in exon-23 skipping. This may not be 
surprising as 1p-TINA-modified oligonucleotides known to destabilize antiparallel duplexes 
(see Table 2.3) [118,119]. As we predicted an increase in the efficiency of skipping by 
introducing another o-TINA towards the 3′-end, we also tested the efficacy of 2o-TINA/ 2′-
OMePS mixmer AO. But, the result showed that the yield of 688 bp skipped product was not 
as high compared the 1o-TINA/ 2′-OMePS mixmer AO. The exon-skipping results are in line 
to the measured Tm of the corresponding duplex, however, the 2o-TINA did show notable 
improvement in inducing exon-skipping in mdx myotubes in vitro corresponding to the 
observed Tm value. 
Interestingly, a minor product band of 542 bp accounting for the dual exon-22/23 skipping 
was also observed in all of the PS-modified AOs samples in yields ranging from 6% to 20% 
(Figure 2.15). Exon-22/23 dual skipping could shift the dystrophin gene reading frame that 
results in the nonsense truncated protein (adverse effect) and therefore should be limited. Fully-
modified 2′-OMePS AO showed the 542 bp dual exon-22/23 skipping product in high yields 
of 17% at 100 nM and 20% at 200 nM concentration. On the other hand, both 1p-TINA/ 2′-
OMePS (11 & 13%) and 1o-TINA/ 2′-OMePS (7 & 14%) mixmer AOs showed the product in 
only low yields at 100 and 200 nM concentration (Figure 2.15). In parallel, we also included 
the normal DNA and RNA AOs on a phosphodiester backbone. Unsurprisingly, both DNA and 
RNA AOs failed to induce any exon-23 skipping, as there was only one band detected at 901 
bp corresponding to the full-length product (Figure 2.15), even after increasing the AOs 
concentration from 100 nM to 200 nM, highlighting the significance of PS backbone to render 





The modified nucleotides p-TINA and o-TINA has been used in PCR application due to its 
ability to form stable triple-helix structure with target, hence increasing the robustness of the 
reaction [120]. In this study, we envisage the use of p-TINA and o-TINA in exon-skipping 
application by incorporating the monomers into 2’-OMePS sequence at either 5’ end (1p-
TINA/ 2’-OMePS and 1o-TINA/ 2’-OMePS AOs) or 5’ end and 1 nucleotide adjacent to 3’ 
end of the AO (2o-TINA/ 2’-OMePS AOs). Results from thermal stability study showed that 
the use of both para and ortho-TINA molecules in the context of 2′-OMePS sequences and 
targeting RNA does not result in significantly increased thermal stability.  
The p-TINA and o-TINA modified 2’-OMePS AOs induced exon-23 skipping in mdx 
myotubes at various level, but not as high as the control fully 2’-OMePS AO. The 1o-TINA/ 
2’-OMePS AO is the best performer that yielded 50% of exon-23 skipping products, in 
comparison to 1p-TINA/ 2’-OMePS AO (42%) and 2o-TINA/ 2’-OMePS AO (38%). This 
result does not correlate with thermal experiment, which is unsurprising due to the discrepancy 
between control environment (in Tm assay) and cellular environment. Furthermore, the 
positioning of the TINA monomers is likely to make contribution to the skipping efficiency of 
the AOs which are under investigated in on-going experiments.  
In addition, we also conducted the cell viability study to test the AOs toxicity. Overall, 
there was no significant difference between the treatments in terms of cell viability. However, 
2o-TINA/ 2′-OMePS AO was found to be non-toxic under the conditions followed by 1o-
TINA/ 2′-OMePS (88%), fully 2′-OMePS control (84%) and 1p-TINA/ 2′-OMePS (83%), 
respectively (Figure 2.16). Although there was variation among the treatments, it was 





Figure 2.16 In vitro cytotoxicity analysis of H2K mdx cells by WST-1 assay after transfected 
with the AO candidates (at 400 nM) in comparison with the untreated cells. UT: untreated. 
Error bars are displayed in SEM of biological duplicates. 
 
4.2.3.4 Conclusions 
AO-mediated exon-skipping therapy is advancing as a potential therapeutic strategy in line to 
recent clinical trials of 2′-OMePS and phosphorodiamidate morpholino (PMO)-based AOs for 
the treatment of DMD. Considering this development, it is important to expand the range of 
chemical modifications to gain more insights on different modifications in splice modulation 
by induced exon-skipping. So far there are no report of using intercalating nucleic acid 
modifications for this purpose, and herein for the first time we investigated the applicability of 
TINA-modified AOs for targeted exon skipping. Introduction of both p-TINA and o-TINA 
together with 2′-OMePS AO did not improve the efficacy of exon-23 skipping, however, the 
dual exon-22/23 skipping was limited compared to the fully-modified 2′-OMePS AO 
counterpart. In our studies, it was clear that o-TINA was found to be a better molecule 
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compared to the p-TINA analogue. Based on the findings, we firmly believe that the exon-
skipping efficiency can be improved by a systematic screening of the positioning of TINA 
monomers in the sequences and also in combination with other chemistries.  
 
4.2.4 AOs modified with serinol nucleic acid (SNA) induces exon-skipping 
in mdx mouse myotubes 
4.2.4.1 Introduction 
Peptide nucleic acid (PNA, Figure 2.17) is a prominent class of acyclic nucleic acid analogues 
and has attracted considerable attention in the field of nucleic acid biology for diagnostic and 
therapeutic applications [121,122]. PNA exhibits very high target binding affinity and form 
extremely stable homo- and hetero-duplex with complementary DNA or RNA [123,124]. In 
addition, PNA also shows very high stability against nucleases [124,125]. However, based on 
previous reports, cell delivery of PNA AOs using normal lipid-based transfection reagents is 
difficult, mainly due to the charge issue [124,125]. To improve this limitation, we envisaged 





Figure 2.17 Structural representations of SNA and PNA oligonucleotide building blocks 
used in this study. 
 
Unlike PNA, SNA building blocks are developed on serinol (2-amino-1,3-propanediol) 
moiety and each monomer units are linked via normal phosphodiester backbone giving them 
negative charge (Figure 2.17) [126]. So far, SNA oligonucleotides have been utilised in 
improving the efficacy of siRNA and for developing molecular beacons for sensitive detection 
of mRNA molecules [127,128]. Generally, SNA oligonucleotides demonstrated high duplex 
stability with complementary RNA oligonucleotides that highlights the potential applicability 
of SNA in developing a robust AO capable of effective transfection with normal lipid-based 
delivery cargos [126]. Herein, we investigated the potential of SNA AO to induce exon-23 
skipping in H2Kb-tsA58 mdx mouse myotubes in vitro and compared its efficacy with PNA AO 





In this study, we investigated the potential of SNA modified AO to induce exon-skipping in 
parallel to PNA modified AO, a closely related analogue, as a control. For this purpose, we 
synthesised a 20-mer fully-modified SNA and PNA AOs including their corresponding 2′-
OMePS AO and 2′-OMePS-mismatch AO controls (Table 2.4), and evaluated their efficacy to 
induce Dmd exon-23 skipping in mdx mouse myotubes.  
First, we performed the melting temperature (Tm) analysis of the AO sequences against a 
20-mer synthetic RNA sequence, which is identical to Dmd gene transcript target as described 
previously [68] (Table 2.4). The results showed that the PNA AO exhibited the 
highest Tm (85.7 °C, Table 2.4) compared to all other tested AOs. However, the SNA AO 
showed higher Tm (62.3 °C) than the 2′-OMePS AO (60.4 °C) and DNA AO (49.8 °C, Table 
2.4). Not surprisingly, the 2′-OMePS-mismatch AO showed very low Tm (33.4 °C) because of 
the impaired Watson–Crick interactions with the RNA target due to mismatched nucleotides. 
 
Table 2.4 AO names, sequences and Tm analysis data used in this study. 
AO names Sequence, 5’- 3’ direction Tm, οC 
PNA P(GGCCAAACCTCGGCTTACCT) 85.7 
SNA S(GGCCAAACCUCGGCUUACCU) 62.3 
2′-OMePS 2’(GGCCAAACCUCGGCUUACCU) 60.4 
DNA GGCCAAACCTCGGCTTACCT 49.8 
2’-OMePS-mismatch 2’(CGCCUAACGUCGGGUAACCA) 33.4 
Complementary synthetic RNA target: 5’-r(AG GUA AGC CGA GGU UUG GCC)-3’. 




Next, we tested the ability of SNA and PNA AOs to induce exon-23 skipping in H2K 
mdx mouse myotubes in parallel to their established control 2′-OMePS AO. In short, the H2K 
mdx myoblasts were cultured as previously and when propagated to 80–90% confluence, the 
cells were plated onto a 24-well plate for differentiation into myotubes [67]. The AOs were 
then transfected into cells at 100, 200 and 400 nM concentrations using a lipid-based 
transfection reagent Lipofectin. After 24 hours, the cells were collected and extracted the RNA 
for analysing exon-skipping efficacy by RT-PCR. The dystrophin transcripts were then 
amplified across exons 20–26 with a full-length product size of 901 bp, and 688 bp product for 
exon-23 skipping. The PCR products were then examined on a 2% agarose gel. The results 
clearly demonstrated that the SNA AO induced exon-23 (full-length band at 901 bp) skipping 
at all concentrations by yielding the skipped product of 688 bp (Figure 2.18), and the skipping 
efficacy was improved at higher doses. Densitometry analysis to quantify the actual percentage 
of skipping showed that the percentage of exon-23 skipped product increased from 41% at 100 
nM to 52% at 400 nM (Figure 2.18). As previously reported, the established 2′-OMePS control 
AO induced efficient exon-23 skipping as low as 100 nM concentration (Figure 2.18). In 






Figure 2.18 RT-PCR and transcript densitometry analysis (aligned with each AO gel 
lane) of RNA prepared from H2K mdx mouse myotubes transfected with full 2′-OMePS, 
SNA, PNA and 2′-OMePS-mismatch AOs. The triangles above the gel images indicate 
increasing AO concentration (100, 200 and 400 nM); FL (full-length) = 901 bp, Δ23 (exon-23 
skipped) = 688 bp, Δ22-23 (exons-22+23 skipped) = 542 bp; (2′-OMePS-mm = 2′-OMePS-
mismatch), UT = untreated, -ve = negative control. Green = exon-23 skipped, blue = exons-
22+23 skipped, grey = full-length. 
 
We then further designed and synthesised an additional mismatched 2′-OMePS (2′-
OMePS-mismatch, Table 2.4) sequence to gain more insights on sequence specificity. Not 
surprisingly, the 2′-OMePS-mismatch AO did not induce any exon-23 skipping at all 
concentrations. In the case of SNA AO, an additional band at 542 bp was observed, and this is 
believed to be due to the undesired dual exon-22/23 skipping (Figure 2.18). 2′-OMePS AO 
showed a higher percentage of dual skipping product (32–37%) compared to the SNA AO (16–
24%) and PNA AO (8%, showed only at 400 nM). 
90 
 
To further investigate the efficacy of exon-23 skipping, the SNA, PNA and 2′-OMePS AOs 
were transfected without using the transfection reagent Lipofectin. The AOs were mixed with 
the media and added directly to the cells (“naked” transfection) and followed the same 
procedure as discussed above. The results showed that all AOs failed to induce any exon-23 
skipping after 24 hours of incubation (Figure 2.19). This experiment highlights that 
complexation with lipid-based transfection reagent is important for effective delivery of SNA 
and 2′-OMePS AOs, and to induce exon-skipping. 
 
 
Figure 2.19 RT-PCR analysis of RNA prepared from H2K mdx mouse myotubes after 
“naked” transfected with full 2’-OMePS, SNA and PNA AOs. The triangles above the gel 
image indicate increasing AO concentration (100, 200 and 400 nM); FL (full-length) = 901 bp; 
UT: untreated, -ve: negative control. 
 
Very high nuclease stability of PNA oligonucleotides has been reported previously, which 
is not surprising in line with its structure [124,125]. Based on this, and to further characterise 
the properties of SNA oligonucleotides, we tested the stability of SNA AO against exonuclease 
degradation using phosphodiesterase I from Crotalus adamanteus venom, in comparison with 
a DNA AO. The AOs were incubated in 0.08 units per ml of the enzyme and samples were 
collected at 0, 10, 30, 60 and 120-minute intervals. The products were then mixed with 
formamide loading buffer and analysed on a 20% denaturing polyacrylamide gel. As predicted, 
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the DNA AO was very vulnerable to nuclease attack and completely degraded within 10 
minutes of incubation. But, the SNA AO showed very high resistance to enzymatic degradation 




Figure 2.20 In vitro stability study of the DNA and SNA AOs against phosphodiesterase I 
from Crotalus adamanteus venom. t: AO template without enzyme, min = minutes. 
 
4.2.4.3 Discussions 
PNA and SNA are prominent class of nucleic acid analogues that possess highly stable duplex 
formation with the complementary DNA or RNA. Utilising this property, we explored the 
ability of using fully modified PNA and SNA AOs for exon-skipping application. Based on 
our study, although PNA AO showed extremely high melting temperature with a synthetic 
complementary RNA, it failed to induce any significant exon-skipping in cell. SNA AO, on 
the other hand, induced efficient exon-23 skipping in H2K mdx myotubes, albeit lower Tm was 
achieved. This may be due to poor cellular-uptake of PNA with normal lipid-based transfection 
reagent Lipofectin as it doesn't complex well. In contrast, SNA AO is negatively charged with 
an inter-nucleotide phosphodiester linkage that make them readily complex with lipid-based 
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transfection reagents and render better cellular uptake capability. It is also noted that the lower 
melting temperature of SNA AO compared to PNA AO could be due to the electrostatic 
repulsion induced by phosphodiester linkage on SNA AO and flexible conformation of SNA 
compared to PNA [129]. In addition, SNA-modified AO also showed very high resistance to 
nuclease degradation, demonstrating potential in therapeutic applications.  
 
4.2.4.4 Conclusions 
In summary, we have synthesised SNA AO and investigated its potential to induce exon-
skipping. We found that SNA-based AO can effectively induce Dmd exon-23 skipping in vitro. 
SNA chemistry is relatively new and has not been explored for therapeutic applications 
compared to PNA. Our study opens up the scope of SNA-modified oligonucleotides in 
developing novel therapeutic oligonucleotides such as AOs, antimiRs, DNAzymes as fully-
modified SNA or in combination with other chemistries (e.g.LNA) [89,90]. 
 
4.2.5 Nucleobase-modified AOs containing 5-(phenyltriazol)-2′-deoxyuridine 
nucleotides induce exon-skipping in vitro 
4.2.5.1 Introduction 
So far, several AOs with sugar and phosphate backbone modifications have been explored for 
their potential to modulate splicing or induce exon-skipping [63,65,76,114,115,130-134]. We 
envisioned the scope of nucleobase-modified AOs to induce exon-skipping. Towards this, 
Nielsen and colleagues reported the synthesis of 5-(phenyltriazol)-2′-deoxyuridines (Figure 





Figure 2.21 Structural presentation of 2’-OMe PS and C5-Phenyltriazole DNA PS nucleic 
acid analogues used in this study. 
 
Improved duplex stability upon incorporation of 5-(phenyltriazol)-2′-deoxyuridine 
nucleotides is believed to be due to the π–π stacking of the aromatic substituents. Herein, we 
describe for the first time that the design and synthesis of 5-(phenyltriazol)-2′-deoxyuridine/2′-
OMe mixmer RNA AOs and evaluate its efficacy to induce exon-skipping in vitro in H2Kb-
tsA58 myotubes. 
 
4.2.5.2 Results  
First, we designed and synthesised two 20-mer 2′-OMePS AOs containing 5-(phenyltriazol)-
2′-deoxyuridine nucleotides in parallel to a previously reported 2′-OMe PS AO [67,68]. The 
first AO sequence (ON1) contained two 5-(phenyltriazol)-2′-deoxyuridine nucleotides at 
positions 10 and 16, and the second AO (ON2) had two consecutive 5-(phenyltriazol)-2′-
deoxyuridine nucleotides at positions 15 and 16 respectively (Table 2.5). To assess the binding 
affinity of the modified AOs against its RNA target, we initially performed the thermal stability 
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analysis using a synthetic complementary RNA sequence (Table 2.5) in parallel to the control 
20-mer 2′-OMePS AO. In line with previous reports [135-138], ON1 containing two 5-
(phenyltriazol)-2′-deoxyuridine nucleotides positioned five nucleotides apart from each other 
showed slight destabilization of the heteroduplex with lower Tm of 58.8 °C compared to the 
20-mer 2′-OMePS control AO sequence (62.9 °C). On the other hand, the AO sequence 
containing two consecutive 5-(phenyltriazol)-2′-deoxyuridine nucleotides showed 
similar Tm (62.8 °C) to the unmodified control 2′-OMePS AO sequence, probably due to 
stronger π–π stacking interaction (Table 2.5). 
 
Table 2.5 AO names and sequences used in this study 
AO names Sequence, 5’- 3’ direction Tm, οC 
2′-OMePS GGCCAAACCUCGGCUUACCU 62.9 
ON1 GGCCAAACCUCGGCTUACCT 58.8 
ON2 GGCCAAACCUCGGCUUACCT 62.8 
Complementary synthetic RNA target: 5’-r(AG GUA AGC CGA GGU UUG GCC)-3’; 5-
(Phenyltriazol)-2’-deoxyuridine monomers are represented in bold underlined letters. 
 
We then evaluated the exon-skipping efficiency of the AOs in vitro using H2Kb-tsA58 
mouse myotubes. Briefly, H2K mdx myoblasts were plated for differentiation into myotubes 
24 h prior to transfection with the AOs using lipid-based delivery agent Lipofectin (2:1 ratio 
of lipo:AO) at 25, 50, 100 and 200 nM. The cells were then collected after 24 hours of treatment 
and the RNA was extracted followed by reverse-transcriptase polymerase chain amplification 
(RT-PCR) analysis by amplifying the product across exon 20–26 as previously reported 
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[67,68]. The results clearly demonstrated that all three AOs efficiently induced exon-23 
skipping in DMD transcript at all concentrations from 25 nM to 200 nM (Figure 2.22) in a 
dose-dependent manner by yielding the skipped product of 688 bp from the full-length 901 bp 
product. The actual exon-skipping efficiencies of the AOs were analysed by densitometry 
(semiquantitative) and the percentage of exon-23 skipping was determined by analysing the 
amount of exon-23 RT-PCR product over the full-length dystrophin product band. 
Densitometry results revealed that the ON1 containing two distantly positioned 5-
(phenyltriazol)-2′-deoxyuridines achieved slightly higher exon-23 skipping efficiency at 25 
nM (57%) and 50 nM (61%) concentrations compared to the control 2′-OMePS AO (51% and 
60% respectively at 25 and 50 nM) (Figure 2.22). However, at higher concentrations, the full 
2′-OMePS AO showed higher exon-23 skipping efficacy (69% at 100 and 70% 200 nM; Figure 
2.22). Notably, ON2 containing two consecutive 5-(phenyltriazol)-2′-deoxyuridines showed 
slightly reduced exon-skipping efficacy at both lower (47 and 54% at 25 and 50 nM, 
respectively) and higher concentrations (57 and 62% at 100 and 200 nM, respectively; Figure 
2.22). This observation does not correlate with the melting temperature analysis data. We 
speculate that this may be due to the structural features of the AO in the cellular environment 
which may distort the AO-target complex because of the positioning of the 5-(phenyltriazol)-





Figure 2.22 RT-PCR and transcript densitometry analysis (aligned with each AO gel 
lane) of RNA prepared from H2K mdx mouse myotubes transfected with ON1, ON2 and 
full 2’-OMePS AOs. The triangles above the gel images indicate increasing AO concentration 
(25, 50, 100 and 200 nM); FL (full-length) = 901 bp, Δ23 (exon-23 skipped) = 688 bp, Δ22-23 
(exons-22+23 skipped) = 542 bp; UT = untreated, -ve = negative control. Green = exon-23 
skipped, blue = exons-22+23 skipped, grey = full-length. 
 
We also observed the presence of another weak product band at 542 bp which is believed 
to be due to the unfavourable dual exon-22/23 skipping (Figure 2.22). All three AOs induced 
the dual exon-22/23 skipping at all concentrations and the intensity increases with increasing 
concentrations, however, the yields were generally very low in all cases, ranging from 15–28%, 
compared to the major expected exon-23 skipped product of 688 bp (51–70%). ON1 induced 
slightly more dual exon-22/23 skipping compared to other AOs at 100 nM (28%), but the 
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percentage reduced to 25% at 200 nM, which is comparable to the control AO (26%) 
and ON2 (24%) (Figure 2.22). 
We then performed the cell viability assay to assess the toxicity of the base-modified AOs 
in parallel to 2′-OMePS AO. Overall, the AOs (2′-OMePS, ON1 and ON2, respectively) were 
found to be relatively non-toxic to cells at 50 nM dose with 95, 96 and 98% cell viable 
compared to the untreated (Figure 2.23). In line with our previous report [130], the 2′-OMePS 
AO was found to be slightly toxic at 200 nM with the cell vitality reduced to 84%, while the 
nucleobase modified ON1 and ON2 maintained 93 and 91% of cell viability respectively at 
200 nM (Figure 2.23). These results may indicate the benefit of incorporating the nucleobase-
modified nucleotides such as 5-(phenyltriazole)-2′-deoxyuridine in reducing the cytotoxic 
effect of the 2′-OMePS AO. 
 
 
Figure 2.23 In vitro cytotoxicity analysis of H2K mdx cells by WST-1 assay after transfected 
with the AO candidates in comparison with the untreated cells. UT: untreated. Error bars are 





Based on our study, it is worth mentioning that the 5-(phenyltriazole)-2′-deoxyuridine building 
block is a logical choice since it is one of the nucleobase-modifications that has demonstrated 
the most positive effects on the thermal duplex stability to date [135], but this property requires 
at least two of these modifications are placed consecutively. Not only is this work the first time 
this building block is incorporated along with 2′-OMe monomers in oligonucleotides 
synthesised on a phosphorothioate backbone, but it is also the first time that this building block 
is examined in vitro in cells for antisense applications. Notably, the current work unintuitively 
demonstrates that the exon-skipping potential of the oligonucleotides is slightly better when 
the 5-(phenyltriazole)-2′-deoxyuridine building blocks are placed distantly compared to 
consecutively, and that the melting temperature (i.e. hybridization strength) is therefore may 
not be necessarily a good indicator for skipping efficiency in the context of the 5-
(phenyltriazol)-2′-deoxyuridine building block. As these are only our preliminary investigation 
towards the application of base-modified AOs in exon-skipping, this finding can help to 
improvise the AO design in future exon-skipping experiments containing base-modified 
nucleotides with multiple chemistries. 
 
4.2.5.4 Conclusions 
In summary, we have designed and synthesized two 2′-OMePS mixmer RNA AOs containing 
two 5-(phenyltriazol)-2′-deoxyuridine monomers placed at distant positions and consecutively, 
and evaluated their potential to induce exon-skipping in DMD transcript using H2K mdx mouse 
myotubes. We found that a 2′-OMePS AO containing two distantly placed 5-(phenyltriazol)-
2′-deoxyuridines induced higher exon-23 skipping at low concentrations, compared to the 
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previously reported control 2′-OMePS AO. Contrary to the melting temperature analysis data, 
the AO containing two consecutive 5-(phenyltriazol)-2′-deoxyuridines were not as effective, 
highlighting the impact of the modified monomer positions. Although we report the first 
demonstration of exon-skipping using nucleobase-modified AOs, further investigations are 
necessary to gain more insights about the positioning and also in combination with other sugar-
modified nucleotides such as locked nucleic acid (LNA) nucleotides [89,90]. Our results open 
the scope of exploring novel base-modified nucleic acid analogues in combination with other 
chemistries for their potential in constructing efficient exon-skipping AOs. 
 
4.3 Overall discussions and conclusions 
This chapter presented the work on synthesis and evaluation of chemically-modified antisense 
oligonucleotides utilising H2K mdx myotubes as a biological model. Novel nucleic acid 
analogues such as HNA, CeNA, ANA, TINA and 5-(phenyltriazol)-2′-deoxyuridines were 
tested for the first time in exon-skipping application. Furthermore, AO stability, cytotoxicity 
and binding affinity were also evaluated in comparison to the published control fully-modified 
2’-OMePS AO. Overall, the findings in this chapter demonstrated the feasibility of using 
modified nucleotide monomers to either enhance the exon-skipping efficiency or reduce the 
cytotoxicity in the tested in vitro model. It would also be ideal to further testing the behavior 
of these modified AOs in an in vivo model system which is more clinically relevant if these are 
to be trialed in clinical settings. 
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Chapter 3.  
Novel splice-modulating antisense oligonucleotides targeting 







Till date, four antisense drugs have been approved by the US FDA [1-5]. These successful 
clinical translations demonstrate the scope of AOs as therapies for tackling various diseases 
including cancer, through either induction of targeted degradation, exon skipping or exon 
retention in the mature mRNA. Angiogenesis is the physiological process of new blood vessel 
growth [6-9]. The discovery of “tumour angiogenesis” nearly 50 years ago has opened up a 
new era in cancer drug development [10-12]. Anti-angiogenesis has been extensively 
investigated in the field of cancer research with over 35000 published reports [13], with various 
strategies have been studied in identifying potential angiogenic markers for therapeutic 
interventions [14-17]. Current cancer therapy involves a combination of different approaches 
including surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy and hormone 
therapy [18]. In the last two decades, advances in antibody-based treatment approaches have 
led to the translation and clinical use of Avastin- a recombinant humanized monoclonal 
antibody targeting vascular endothelial growth factors (VEGF-A) [19,20] and Cyramza- a fully 
human monoclonal antibody targeting vascular endothelial growth factor receptor (VEGFR2) 
[21,22] that gained US FDA approval in 2004 and 2014, respectively for the treatment of 
several cancer types and age-related macular degeneration. However, antibody-based anti-
angiogenic therapies for cancer are costly and commonly showed mild to serious toxic side 
effects in cancer patients [23,24]. 
Unlike antibodies, AO-based approaches can target the hallmark pathologies at the RNA 
level by sequence-specific binding of a synthetic AO to modulate the expression of pro-
oncogenic genes [25-27]. To evaluate the potential therapeutic benefits of utilising AO 
targeting angiogenic factors in solid cancer, this chapter focuses on exploring the design, 





2. Antisense oligonucleotides approach targeting angiogenic factors in 
cancer 
Various angiogenic factors [28] such as basic fibroblastic growth factor (bFGF) [29,30], 
epidermal growth factor (EGF) [31,32], platelet derived growth factor (PDGF) [33,34], 
transforming growth factor (TGF)-α [35,36] and β [37,38], VEGF-A [39,40], endoglin 
(CD105) [41,42], and angiopoietins (ANGPT1, 2, 3, 4) [43,44] are discussed below, regarding 
their characteristics, current and future approaches as potential targets for AO-mediated 
therapeutic intervention. 
 
2.1 Basic fibroblast growth factor (bFGF) 
First described by Gambarini et al. [45] as an active protein in pituitary extracts that can 
promote the growth of 3T3 cells, bFGF (also known as FGF-2 or FGF-β) was later 
characterized as a basic polypeptide possessing mitogenic activity. Embedded in the basement 
membranes and the sub-endothelial extracellular matrices of blood vessels, bFGF is a potent 
mitogen for vascular and capillary endothelial cells involved in angiogenesis [46]. 
Inhibition of bFGF using AOs could decrease angiogenic activity in solid cancers. Ensoli 
and colleagues reported that phosphorothioate-modified AOs targeting bFGF mRNA in cells 
from Kaposi’s sarcoma lesions efficiently reduced the cell growth and associated angiogenic 
activity [47]. A similar result was observed in cells derived from nude mice inoculated with 
AIDS-KS cells. In another study, Murphy et al. demonstrated that AO treatment decreased the 
doubling time of the U87-MG glioblastoma cell line by two folds and reduced the cell number 
to 32% and showed that both 23- and 25-kDa isoforms of bFGF were reduced by 64% and 
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73.3%, respectively, in comparison to the untreated [48]. Using short 15-mer AOs targeting 
bFGF mRNA, Bernardini et al. showed a significant decrease of up to 89% in the proliferation 
of V9/AP4 Chinese hamster fibroblasts at 60 µM concentration, compared to the untreated 
cells, indicating an important role for bFGF in cell growth and survival [49]. In a study by 
Becker et al., three 15-mer unmodified oligodeoxynucleotides targeting the bFGF mRNA 
translation initiation site in human vertical phase melanoma cells, derived from melanoma 
WM75 showed 50-75% inhibition in cell growth [50]. Expression of bFGF was significantly 
higher in the human glioma cell line, SNB-19, that may enable neoplastic progression of 
gliomas [51,52]. Morrison and colleagues showed that an AO targeting the first donor-acceptor 
splice sites of the bFGF mRNA effectively reduced SNB-19 cell growth by 68%, compared to 
the neutralizing bFGF antibody (48%) and an antagonist (inositol hexakisphosphate) (44%) 
[53]. 
The translation initiation factor eIF4E has been linked with increased bFGF expression in 
breast cancer cells [54]. AO-targeting of eIF4E effectively reduced tumour vascularization and 
metastasis, coherently associated with the loss of bFGF [55]. Similarly, another study has 
shown that AOs directed against the transforming growth factor β (TGF-β) abrogated the anti-
proliferative effects and inhibited the induction of p21/WAF1/CIP1 by bFGF in MCF-7 breast 
cancer cell lines [56]. bFGF was also found to contribute to growth of non-small cell lung 
cancer, and down-regulation of bFGF using AOs in combination with a monoclonal antibody 
showed a significant reduction in cell proliferation [57]. Among the growth factors, bFGF plays 
a critical role in angiogenesis of renal cell carcinoma. Cenni et al. has utilised a 
phosphorothioate-modified AO targeting bFGF mRNA in the Caki-1 renal carcinoma cell line 





2.2 Epidermal Growth Factor (EGF) and EGF receptors 
Epidermal growth factor (EGF) plays a crucial role in regulating cell growth, differentiation 
and proliferation [32]. First detected in the submaxillary gland of the mouse in 1962, this 
“growth-promoting” protein and its receptors have now emerged as potential targets for wound 
healing and cancer therapy [60,61]. EGF functions through the interaction with tyrosine kinase 
receptor ErbB family. The ErbB family includes EGFR (ErbB1/HER1), ErbB2 (HER2/neu), 
ErbB3 (HER3), and ErbB4 (HER4) that create a complex network of signaling pathways 
[62,63]. Aberrant EGFR signaling is believed to be involved in the pathogenesis of many 
human diseases, including various types of cancers. EGFR is also recognized as the primary 
receptor target for developing monoclonal antibody therapies in cancer [63]. 
Protein localization studies performed on squamous cell carcinoma of the head and neck 
(SCCHN) suggested increased expression of EGFR and transforming growth factor (TGF-α) 
in SCCHN cells [64]. To determine the effect of EFGR inhibition on SCCHN cell growth, AOs 
were directed against the translation initiation site and at the first intron-exon splice junction. 
As a result, the cell growth was reduced by 80%, 6 days after combined treatment with both 
AOs, compared to untreated cells [64]. Follow-up studies showed that a combination of 
docetaxel and an EGFR mRNA targeting phosphorothioate AO via RNase-H recruitment 
synergistically inhibited SCCHN cell proliferation in vitro, and also reduced tumour volume in 
a xenograft mice model [65]. In another study, Low and colleagues reported the design of AOs 
(AEGFR2, AEGFR2S) targeting positions 3811-3825 of the EGFR cDNA for down-regulation 
of EGFR through RNase-H mechanism [66]. The AOs were then encapsulated in folate-PEG-
liposomes for delivery into cultured KB cells. Remarkably, the AO complex effectively 
reduced KB cell proliferation by 90% after 48 hours of treatment, compared to untreated cells, 
5-fold more effective than the AEGFR2 AO encapsulated in a non-targeted liposome.   
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EGF-related peptides, such as TGF-α, amphiregulin (AR) and CRIPTO-1 (CR) also 
proved to be attractive targets in experimental cancer treatments. De Luca et al. suggested that 
combinations of AOs targeting different growth factors might be a relevant approach for 
treating human colon carcinomas [67,68]. In their study, 10 AOs were designed against TGF-
α, CR and AR; all of which were synthesized as either full DNA or as gapmers with 2′-O-
Methyl RNA on a phosphorothioate backbone. Different AO cocktails were tested in human 
colon cancer GEO cell line and the most effective showed approximately 50% reduction of 
AR, CR and TGF-α protein expression when transfected at 1 µM concentration for 48 hours, 
compared to the untreated cells. A dose of 10 mg/kg inhibited tumour growth by 60 - 65% 
when injected into nude mice carrying GEO xenografts, compared to those treated with the 
scrambled sequence control. An “additive growth-inhibitory” effect was observed when the 
AOs were combined with conventional anti-tumour drugs, such as 5-fluorouracil, adriamycin, 
mitomycin C and cis-platinum in GEO cells, increasing the efficacy to 70% reduction [67]. 
Notably, these EGF-like growth factors also found to be overexpressed in ovarian carcinoma 
cells. Casamassimi et al. reported reduction in anchorage-dependent growth of NIH:OVCAR3 
and NIH:OVCAR8 cells when treated with AOs directed against amphiregulin, CRIPTO-1 and 
TGF-α [69]. 
 
2.3 Platelet-derived growth factor (PDGF) 
Platelet-derived growth factor (PDGF) is a dimeric glycoprotein composed of two distinct, but 
related chains, termed A and B [70]. PDGF plays important roles in cell growth stimulation, 
cell migration and activation, and is also implicated in different diseases and conditions, 
including wound repair, atherosclerosis and cancer [71]. Sato et al. revealed that PDGF-BB is 
capable of enhancing in vitro capillary formation through direct action on myofibroblasts in an 
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angiogenesis model using the rat microvascular fragments and myofibroblasts [71]. This 
suggests that PDGF-BB plays a trivial paracrine role in the process of angiogenesis. 
Additionally, PDGF also acts as an autocrine stimulatory signal in regulating cell growth. 
Schlingensiepen and colleagues investigated the effect of PDGF-AA on HTZ 19 melanoma 
cells proliferation [72]. AOs targeting PDGF-A mRNA for degradation reduced cell growth in 
vitro by 62% when applied at 5 µM concentration for 48 hours. In another study, Yamamoto 
et al. reported that advanced glycation endproducts (AGE) can stimulate growth of MIA PaCa-
2 pancreatic cells by upregulating PDGF-B mRNA levels through interaction with the cell 
surface receptor for AGE (RAGE) [73]. AOs targeting RAGE mRNA reversed this process. 
Vascular smooth muscle cells (VSMCs) proliferation has been linked to diseases such as 
hypertensive vascular diseases, restenosis of coronary arteries after angioplasty, and 
atherosclerosis. Fukuda and colleagues explored the use of an antisense peptide nucleic acid 
(PNA) to study the effect of PDGF-A chain expression on VSMCs growth [74]. A 15-mer PNA 
oligomer was designed complementary to a region including the initiation codon of rat and 
human PDGF-A-chain mRNA. Not surprisingly, DNA synthesis in VSMCs cells was reduced 
by 6 folds when the AO was transfected at 0.5 µM, compared to the control PNA oligo, 
suggesting that PDGF-A chain expression might regulate VSMCs proliferation and can serve 
as a potential therapeutic target for abovementioned diseases. 
 
2.4 Transforming growth factor-alpha (TGF-α) 
TGF-α, initially termed EGF-like TGF (eTGF), is a mitogenic polypeptide, structurally related 
to EGF that can bind to EGFR and promote angiogenesis [75,76], and known to be secreted by 
a wide range of human tumours [77]. Sizeland et al. reported that a 23-mer DNA AO targeting 
the translation start site of TGF-α inhibited DNA synthesis (measured via 3H-thymidine uptake) 
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in LIM 1215 colon cancer cell by 97% when applied at 50 µM concentration, and completely 
suppressed cell proliferation 5 days after transfection at 10 µM [78]. Another study conducted 
by Grandis et al. showed that TGF-α also contributed to an autocrine signaling pathway in head 
and neck cancer [79]. To examine the effect of TGF-α down-regulation on cell proliferation, 
the authors transfected SCCHN cells with a 19-mer phosphorothioate DNA AO targeting TGF-
α mRNA. At 12.5 µM concentration, the AO showed higher efficacy, with 76% inhibition of 
SCCHN cell growth and 93% downregulation of TGF-α protein, 6 days after transfection. 
Normal mucosal epithelial cell proliferation was not affected by the AO treatment that induced 
an 83% reduction in TGF-α protein, suggesting an autocrine function for TGF-α in regulating 
malignant tumour growth [79]. Studies led by Rubenstein and colleagues reported AO targeting 
of TGF-α in human-derived prostate tumour cells [80,81]. Two gapmer AOs containing 3’ 
phosphorothioate linkages at each end were directed against the translation initiation sites of 
the TGF-α and EGFR transcripts in PC-3 prostate cancer cells. The AOs showed significant 
inhibition of PC-3 cell growth in vitro; and were effective in inducing hemorrhagic necrosis in 
PC-3 tumours in vivo in athymic nude mice. To enhance the efficacy of the AOs, Rubenstein 
et al. continued their work by designing bispecific AOs recognizing the binding sites of TGF-
α and EGFR mRNA; and EGFR and Bcl-2 mRNA and tested in both MCF-7 breast cancer cells 
and PC-3 prostate cancer cells [82]. Notably, MCF-7 cells were more responsive to 
monospecific AOs, whereas the bispecific AOs performed better in PC-3 cells, in line with 
previous observations by the authors. Combination therapy involving rapamycin/paclitaxel and 
mono or bispecific AOs showed improved efficacy [82]. 
 
2.5 Transforming Growth Factor-beta (TGF-β) 
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Despite sharing the same prefix as TGF-α, TGF-β is in fact a distinct class of growth factor 
that includes four different isoforms: TGF-β1 to 4, forming the TGF-β superfamily. First 
described by de Larco and Todaro [83] in 1978 as sarcoma growth factors (SGFs), the 
polypeptides are neither structurally nor genetically related to TGF-α, as they function through 
different pathways and interact with distinct receptors. While TGF-α is well-known for 
promoting angiogenesis, TGF-β signaling is involved in many cellular processes, such as 
proliferation, differentiation and apoptosis [37,38]. In addition, the growth factors also 
modulate extracellular processes such as cell invasion, immune regulation, and 
microenvironment modification [84]. Several therapeutic approaches targeting the TGF-β 
pathway have been proposed, including utilization of antisense oligonucleotides against the 
TGF-β mRNA, antibodies and small molecule inhibitors of TGF-β receptors [85,86]. During 
carcinogenesis, the role of TGF-β signaling as a tumour-promoter or tumour-suppressor is still 
under debate. Luwor et al. suggested that the growth-regulatory effects of TGF-β in tumour 
development is a two-stage process: “TGF-β-inhibited” at early stages before switching to the 
“TGF-β-promoted” stage that triggers tumour growth and invasiveness [87]. Others suggested 
that TGF-β1 has positive effects on T-cell proliferation and cytokine production [88], whereas 
suppression of TGF-β2 in glioma models has been shown to prevent immunosuppression of 
lymphocytes in vitro [89]. 
Wright and colleagues [90] described the design and synthesis of AOs targeting TGF-β1 
mRNA and investigated the effects on H-ras transformed fibrosarcoma cells. At 1 µM 
concentration, all AOs were able to inhibit cell proliferation and induce morphological changes 
in a non-specific manner. However, the AO termed AS-5-OSO containing a mixture of 
phosphorothioate and phosphodiester linkages caused a 50% reduction in cell growth, in 
comparison with the untreated cells. Additionally, this AO also markedly reduced the invasive 
and metastatic effects of the fibroscarcoma cells, highlighting the importance of AO design 
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and chemistry, with mixed linkages conferring greater specificity and lower toxicity, compared 
to AOs composed of only phosphorothioate linkage [90]. 
Malignant mesothelioma (MM) is an aggressive tumour that is refractive to conventional 
cancer treatments, due to the acquired mechanisms that augment the ability of tumour cells to 
survive and proliferate. Marzo et al. assessed the hypothesis that TGF-β contributes directly or 
indirectly to MM growth and tumourigenesis, using DNA AOs targeting TGF-β1 and TGF-                                                                                    
β2 mRNA in AC29 murine MM cell line [89]. Following transfection, the AOs induced 50% 
inhibition of AC29 cell proliferation over a 4-day period. To determine the effect of the AOs 
in vivo, tumour-bearing CBA/CAH (H-2k) mice were injected intra-tumourally with a TGF-β2 
phosphorothioate AO. There was a substantial reduction in TGF-β2 mRNA within mice after 
5 days of treatment with the AO, but the reduction effect was halted after 9 days of treatment 
[89]. 
Bogdahn and coworkers employed 14-mer phosphorothioate AOs targeting TGF-β1 and 
TGF-β2 mRNA in 12 patient-derived glioma cell lines HTZ-10, -60, -340, -70, -243, -262, -
85, -119, -121, -209, -326, -341 [91]. Of the 12 cell lines tested, TGF-β1 targeting AOs were 
able to reduce cell growth in 6 cell lines (HTZ-10, -85, -209, -243, -262, -326). The TGF-β2 
targeting AOs showed inhibitory effect in all 12 cell lines, and also reduced the amount of 
secreted TGF-β1 and TGF-β2 proteins, suggesting that TGF-β2 plays a major role in regulating 
glioma cell proliferation. Evidence also shows that an increase in TGF-β2 secretion in glioma 
cells can lead to an immunosuppressed state that could be responsible for the failure of various 
immunotherapy strategies. Lillehei and colleagues showed the promise of antisense approach 
to overcome tumour-induced immunosuppression and enhance tumour vaccine efficiency in 
high-grade gliomas [92]. Tumour-bearing rats were treated with an AO specific for TGF-β2 
mRNA in combination with systemic tumour vaccine and monitored the survival rate. The life 
span of the treated rats was significantly increased with mean survival time (MST) of 48.0 
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days, in comparison to vaccine alone (29 days), AO alone (37.5 days) or phosphate buffer 
saline alone (31.5 days).  
The potential of AO therapeutics was also evaluated in oral squamous cell carcinoma 
(OSCC). Kim et al. designed and assessed the efficacy of an 18-mer DNA AO targeting TGF-
β1 in SCC-9 cells [93]. AO-treated SCC-9 cells showed a significant decrease in TGF-β1 
expression and cell growth, compared to the untreated cells. In addition, the AO treatment 
reduced the tumour size in vivo by approximately 50%, and diminished the expression of a 
proliferating cell nuclear antigen (PCNA) and matrix metalloproteinase (MMP2), well 
established indicators of cell proliferation. The AO AP12009 (Trabedersen), developed by 
Antisense Pharma GmbH, targets the TGF-β2 transcripts and has entered phase I/II clinical 
trials for the treatment of high-grade glioma, pancreatic cancer and malignant melanoma [94]. 
  
2.6 Vascular endothelial growth factor (VEGF) 
Angiogenesis is crucial for tumour development. First described as a mitogenic soluble factor 
responsible for new capillaries formation, vascular endothelial growth factor (VEGF), vascular 
permeability factor (VPF) or tumour angiogenesis factor (TAF) has now been identified as a 
key regulator of tumour angiogenesis [11,12]. VEGF, one of the most extensively studied 
growth factors to date, is widely known for its potential in cancer treatment and the roles of 
VEGF and Flk-1/KDR receptor tyrosine kinase have been implicated in cancer pathology [95]. 
Over-expression of VEGF has been observed in different human cancers, including breast, 
liver, colorectal, brain, ovarian and non-small cell lung cancer. Previous studies found that 
increased vascularization induced by VEGF plays an important role in tumour progression and 
metastasis [40]. Splicing of VEGF pre-mRNA generates several VEGF isoforms and the 
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predominant ones are VEGF-165, VEGF-121 and VEGF-189, which are over-expressed in 
many cancer cell types [96]. 
Gill and coworkers demonstrated the use of AOs to inhibit VEGF mRNA in Kaposi 
sarcoma (KS) [97]. Six different cell lines including AIDS–KS cells, HUVEC, AoSM, Hut-78, 
23-1 (a B lymphoma cell line), and T1 (a fibroblast cell line) were cultured and seeded into 24-
well plates. The cells were then treated with five 21-mer DNA AOs containing 
phosphorothioate linkages designed to target the human VEGF coding region at concentrations 
ranging from 1 to 10 µM. The results showed that two AOs (AS-1 and AS-3) showed 
significant inhibition of KS cell growth in a dose-dependent manner, ranging from 53% (1 µM) 
to 81% (10 µM), compared to untreated cells. In contrast, the inhibitory effect was minimal for 
HUVEC (17%) and AoSM (26%) cells at 10 µM. The efficacy of the AOs was also confirmed 
with reduction of VEGF protein by 80% in KS cells treated with AS-3 at 5 µM. To further 
examine AO efficacy, nude mice inoculated with KSY1 cells were injected daily with AS-1, 
AS-3 or a scrambled AO at 25 µg/g body weight for 5 days. After 14 days, tumours within 
mice treated with AS-1 and AS-3 showed 85% and 88% reduction in size, respectively when 
compared with untreated mice. Ciardiello et al. later explored the combination effect of AS-3 
and an anti-EGFR monoclonal antibody (MAb) C225 in human GEO colon cancer cells [98]. 
The group synthesized AS-3 with a phosphorothioate backbone and treated the cells with either 
MAb alone, AS-3 alone or in combination. In line with the previous report, AS-3 reduced 85% 
of VEGF protein expression at 5 µM concentration. The outcome of in vivo experiments in 
immunodeficient mice (AS-3: 10 mg/kg/dose and MAb C225: 0.5 mg/dose) demonstrated the 
synergistic effect of AS-3 and the MAb. Analysis of the tumours after 21 and 28 days of 
combination therapy showed 95% and 98% of VEGF protein inhibition, compared to 90% and 
92% when treated with AS-3 alone, and 75% and 70% when treated with MAb alone. 
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Interestingly, 50% of the mice under combination treatment survived after 13 weeks, whereas 
all other groups died within 8 weeks of treatment [98].  
Renal cell carcinoma (RCC) is a highly vascularized tumour that accounts for almost 2% 
of all adult malignancies. VEGF over-expression has been observed in Caki-1- a RCC cell line. 
Shi and Siemann reported the design of a 20-mer DNA AO on a phosphorothioate backbone 
(V515) complementary to 5′ UTR region of VEGF mRNA [99]. Cationic liposome (prepared 
by mixing 1,2-dioleoyloxy-3- (trimethylammonium) propane (DOTAP) with a helper lipid 1,2-
dioleoyl-3-sn-phosphatidylethanolamine (DOPE)) was used as transfection agent to deliver 
V515 into Caki-1 cells. After 24 hours of treatment, VEGF levels were reduced in a dose-
dependent manner, ranging from 35% to 85% at 0.5 µM and 2 µM concentrations, respectively. 
Importantly, VEGF inhibition also affected endothelial cell growth and migration. Co-culturing 
of treated Caki-1 cells with either mouse heart endothelial (MHE) cells or human microvascular 
endothelial cell from the lung (HMVEC-L) indicated a significant decrease in both MHE (43%) 
and HMVEC-L (67%) cell proliferation and migration. In vivo injection with two doses of 
V515 (5 mg/kg) in Caki-1 xenograft-bearing mice triggered a 5.5 days delay in tumour growth, 
while two doses of 10 mg/kg resulted in an 8 days delay [99]. 
Exploring indirect targets towards VEGF inhibition has also offered attractive therapeutic 
avenues. One alternative approach is to target tyrosine kinase receptors (KDR/Flk-1 and Flt-1) 
to block the interaction between VEGF and its receptors. Shimada and coworkers studied the 
effect of AO on peritoneal dissemination and angiogenesis in human gastric cancer (HGC) 
[100]. After 5 days of AO incubation with the cells, including HUVEC, PC-3 and NUGC-4, 
growth rate of all cell lines except NUGC-4 decreased to 43.6% (HUVEC) and 49.1% (PC-3), 
compared to untreated cells. NUGC-4 cells were not affected by the AO treatment. Notably, 
KDR/Flk-1 protein expression in PC-3 treated cells was reduced to 42%. Subsequently, 
NUGC-4 cells were transduced with GFP and implanted into BALB/c nu/nu male mice. Anti-
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VEGF AO was then injected intraperitonially for 8 days at 200 µg/mouse/day. After 14 days 
of treatment, 80% of the tumour nodules in treated mice could not be visualized by fluorescent 
microscopy. Tumour angiogenesis was significantly inhibited (95% compared to the untreated 
group); and showed increased tumour apoptosis (50%) [100]. Förster et al. also assessed the 
efficiency of AO targeting VEGF in MCF-7 breast cancer and EJ28 bladder cancer cell lines 
[101]. The authors designed 25 AOs (20-mer) against VEGF and transfected these compounds 
into MCF-7 and EJ28 cell lines. Following transfection, ELISA analysis revealed 83.5% and 
48.9% inhibition of VEGF protein expression in EJ28 and MCF-7 cells, respectively with the 
most effective AO (VEGF723) at 1 µM concentration. Further examination showed up to 79% 
inhibition of EJ28 cell proliferation was achieved with AO VEGF723 after 20 hours of 
treatment [101].  
Hörmann and colleagues observed significant induction of VEGF secretion from head and 
neck squamous cell carcinoma (HNSCC) UMSCC22b cells (approximately 3.5 and 2.75 folds 
above normal) upon treatment with chemotherapeutic agents, such as Carboplatin (doses at 90 
µg/ml) and Cisplatin (2.5 µg/ml) in treated cells relative to sham control cells [102]. The 
authors then designed a 21-mer phosphorothioate DNA AO complementary to the translation 
start site of human VEGF gene and evaluated the AO efficacy in UMSCC22b cells treated with 
chemotherapeutic agents. After 48 hours of AO treatment, VEGF level was significantly 
reduced by up to 4 folds compared to controls [102].  
Treatment of unresectable hepatocellular carcinoma (HCC) is challenging and 
transcatheter arterial embolization (TAE) is the accepted treatment strategy. However, the 
tumour cannot be treated completely, and 3-year survival rate of the patients stumbles at 14-
35%. There are reports on increased VEGF production in both HCC cells and non-carcinoma 
liver cells prior to TAE. Wu et al. transfected a 22-mer phosphorothioate DNA AO targeting 
the linkage area of exon 2 and 3 of VEGF mRNA into Walker-256 carcinosarcoma cells at 
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different concentrations (0.25, 0.5, 1.0, 2.0 µM) [103]. At 48-hour time-point, secreted VEGF 
levels were found to have been decreased in a dose-dependent manner, ranging from 7% at 
0.25 µM to 28% at 2.0 µM, compared to controls. For analyzing the efficacy in vivo, rats were 
implanted with Walker-256 cells and then treated with either 0.2 mL Lipiodol (LP), LP+AO 
or normal saline. MR scans of the LP and LP+AO groups showed substantial reduction in 
growth rate, in comparison to the control group [103]. 
VEGF also plays an important role in the development and metastasis of pancreatic cancer. 
Based on earlier reports, Hotz et al. transfected their AS-3 AO [97] sequence, complementary 
to VEGF cDNA base +261 to +281, into AsPC-1 and HPAF-2 pancreatic cancer cells at a 
concentration of 5 µM and examined the results 36 hours later [104]. Western blot analysis 
showed a remarkable reduction in VEGF protein expression in both cell lines. Later, nude mice 
injected with either AsPC-1 or HPAF-2 cells were treated with AS-3 at 10 mg/kg/day 
intraperitoneally for 14 weeks. An 80% reduction in tumour volume was observed in HPAF-
2-innoculated mice, but not in the other group. Also, metastasis ability was significantly 
dropped in both groups, and microvessel density was recorded a reduction by at least 50% in 
both groups [104].  
To investigate the feasibility of VEGF-targeting antisense therapy in acute myeloid 
leukemia (AML), Ding et al. transfected HL-60 cells with 0.3 µM VEGF AO. A reduction in 
cell growth of nearly 50% was observed, in addition to enhanced chemo-sensitivity of the cells 
to arsenic trioxide (ATO), a traditional component of Chinese medicine [105]. The synergistic 
effect of AO and ATO was further proved its efficacy to inhibit VEGF protein production by 
50% in treated cells. 
 
2.7 Endoglin (CD105) 
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Endoglin (CD105) is a homodimeric hypoxia-inducible transmembrane glycoprotein. Initially 
recognized as an antigen produced against human pre-B leukemic cell line, the peptide was 
named “44G4” because of its reaction with mAb 44G4 [41,106]. Recent advances have gained 
more insights on its role as a co-receptor for TGF-β in endothelial cell signaling pathway. High 
levels of endoglin are expressed in continuously proliferating endothelial cells, making 
endoglin a logical target for cancer treatment [42]. Trophoblast growth and invasion are 
essential for normal placenta development, and the TGF-β signaling pathway has been 
identified as one of the main drivers for this process. Endoglin is expressed at high levels 
throughout pregnancy and binds to TGF-β1 and -β3 isoforms. Caniggia et al. used a 16-mer 
phosphorothioate DNA AO targeting the translation initiation codon of human endoglin 
mRNA and demonstrated that the AO, after transfection at 5-10 µM, promoted the outgrowth 
and invasiveness of extravillous trophoblasts (EVT) in a human trophoblast villous explant 
culture, presumably due to endoglin and TGF-β inhibition [107]. Kumar and coworkers treated 
HUVEC cells with a 16-mer phosphorothioate DNA AO to explore the effect of endoglin on 
endothelial cell behavior [108]. The results indicated that endoglin protein levels were inhibited 
by 62% at 0.25 µM concentration after 72 hours. Further analysis revealed that the AO-treated 
cells were more sensitive to TGF-β1, which reduced the growth and migration rate significantly 
by 38%, compared to the untreated cells. Endoglin was also implicated to be involved in 
hypoxia-initiated angiogenesis. Li et al. assessed the effect of a 16-mer phosphorothioate DNA 
AO on endoglin expression in human dermal microvascular endothelial cells (HDMECs) [109]. 
After 48 hours in normoxia, the transfected cells were exposed to hypoxic condition for 24 hr. 
A significant increase (86.3%) in endoglin protein levels was observed in untreated cells, but 
the AO-treated cells possessed suppressed endoglin protein level (55-60%). Additionally, 
treated cells showed a significant increase in cell apoptosis (62%) compared to untreated cells 




2.8 Angiopoietin family 
The angiopoietin (ANGPT) family consists of ANGPT1, ANGPT2, ANGPT3 and ANGPT4 
and were all discovered as VEGF-related factors [110-112]. Apart from ANGPT3, an ortholog 
in mouse, the other three ANGPTs are expressed in humans and play complex roles in 
angiogenesis and vascular remodeling due to their interactions with each other and the Tie-2 
tyrosine receptor. To investigate the effect of ANGPT on endothelial cell survival, Li and 
colleagues constructed a 25-mer phosphorothioate DNA AO targeting bovine Tie-2 mRNA 
and transfected this compound into cultured adult bovine aortic endothelial (ABAE) cells 
[113]. At a concentration of 150 nM, the AO induced 90% cell death, compared to the untreated 
cells. Further evaluation showed a 6-fold increase in cell apoptosis induced by AO treatment 
relative to control cells. Boulton and coworkers [114] explored the function of ANGPT 
signaling system in diabetic retinopathy using the same AO reported earlier by Li et al [113]. 
The Tie-2 AO was transfected into bovine retinal pericytes at 6 µM to evaluate its effect on 
cell survival and proliferation. Tie-2 inhibition reduced ANGPT1 expression and significantly 
decreased pericyte migration. These findings clearly indicated that targeted regulation of 
ANGPT isoforms could be a feasible approach in diabetic retinopathy treatment. 
 
2.9 Clinical trials 
Clinical trials employing all investigational therapeutic molecules and antisense therapeutic 





Table 3.1 Approved drugs and clinical trials targeting angiogenesis factors in cancers.* 





Drug Type Target tumour Refs 
APPROVED DRUGS 

















Approved drug Small molecule Renal cell carcinoma [117] 
4 Bevacizumab/ Avastin VEGF-A Approved drug 
Monoclonal 
antibody 








Approved drug Small molecule 
Medullary thyroid 
cancer, advanced renal 
cell carcinoma 
[118] 





small cell lung cancer, 
head and neck cancer 
[119, 
120] 
7 Erlotinib/ Tarceva EGFR Approved drug Small molecule 
Advanced 
or metastatic non-







8 Gefitinib/ Iressa EGFR Approved drug Small molecule 





9 Icotinib/ Conmana EGFR Approved drug Small molecule 
Non-small cell lung 
cancer 
[124] 





11 Lenvatinib/ Lenvima VEGFR 1,2,3 Approved drug Small molecule 
Differentiated thyroid 













13 Osimertinib/ Tagrisso EGFR Approved drug Small molecule 
Specific non-small cell 
lung cancer (T790M 
mutation) 
[128] 
14 Panitumumab/ Vectibix EGFR Approved drug 
Monoclonal 
antibody 
Colorectal cancer [129] 




Approved drug Small molecule 
Renal cell carcinoma, 
soft tissue sarcoma 
[130] 















18 Regorafenib/ Stivarga 
VEGFR2, 
TIE-2 










Approved drug Small molecule 
Advanced renal cell 
carcinoma, advanced 






20 Sunitinib/ Sutent 
VEGFR/ 
PDGFR 
Approved drug Small molecule 





21 Temsirolimus (CCI-779) mTOR Approved drug Small molecule Renal cell carcinoma [136] 
22 Tivozanib/ Fotivda VEGFR 1,2,3 Approved drug Small molecule Renal cell carcinoma [137] 






Breast cancer [138] 










25 ALN-VSP02 VEGF, KSP 
Investigational 
drug (Phase I 
trial) 
siRNA 

















27 AZD4547 FGFR 
Investigational 
drug (Phase II 
trial) 
Small molecule 














29 Cediranib/ Recentin VEGFR 
Investigational 



















31 Fresolimumab TGF-β1,2,3 
Investigational 





and renal cancer 
[148] 
32 hVEGF26-104/RFASE VEGF 
Investigational 
































35 PTC299 VEGF 
Investigational 






36 Rindopepimut EGFR 
Investigational 
drug (Phase III 
trial) 
small molecule Glioblastoma [155] 
37 Sevacizumab VEGFA 
Investigational 




Colorectal cancer [156] 
38 Sym004 EGFR 
Investigational 








39 TRC105 Endoglin 
Investigational 













drug (Phase I 
trial) 
















42 VEGF-AS/ Veglin VEGF 
Terminated 







* Table was arranged based on alphabetical order of drug name. 
 
3. Exploring novel splice-modulating antisense oligonucleotides targeting 
VEGF as potential molecules for cancer therapy 
3.1 Introduction 
Vascular endothelial growth factor A (VEGF-A) is a key regulator of angiogenesis, a process 
that drives the formation of new blood vessels towards the tumour and play a vital role in cancer 
progression and metastasis [7-14,40,162-164]. Previous studies have shown the overexpression 
of VEGF-A in a numerous type of cancers such as glioblastoma, medulloblastoma, 
hepatocellular carcinoma, adeno carcinoma and breast cancer [165-169]. It is now more evident 
that the functions of VEGF-A are not restricted to angiogenesis. Recent studies reported that 
VEGF contribute to different processes including the regulation of immune cells in tumor 
microenvironment [170], promoting cancer cell stemness and accelerating the recurrence of 
cancer [171], and enhancing the survival of cancer stem cells along with formation of 
aggressive and highly vascularized tumors [172]. VEGF is also implicated in the suppression 
of anti-tumor immune response via the association with CD4+ forkhead box protein P3 
(FOXP3)+ regulatory T cells. Sequestering VEGF increases the activation of CD8+ T cell which 
lead to the reduction in tumor growth [170]. Recently, Liu et al. demonstrated that an increase 
of plasma VEGF after radiotherapy advocates tumor stemness and tumorigenesis of 
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hepatocellular carcinoma [171]. Studies also suggested that VEGF upregulates two 
transcription factors cMyc and Sox2 that involved in self-renewal ability of stem cells, which 
indicates an important role of VEGF in driving the cancer stem cell population development 
[173]. 
Anti-VEGF therapy for solid cancers has been studied extensively in the past decades to 
block either the expression of VEGF or the interaction between VEGF and its receptors [174-
176]. Another approach is to manipulate the balance between pro-angiogenic VEGF and anti-
angiogenic VEGF-b isoforms, although this hypothesis is currently under debate since more 
evidences are required to confirm the existence of VEGF-b isoforms [96,177-181]. To date, 
the US FDA has approved several antibody-based and small molecule drugs targeting VEGF 
pathway (Table 3.1) including the two most popular drugs that target VEGF-A: Bevacizumab 
and Aflibercept (Table 3.2), but the efficacy and side effects still leave a big question mark 
[20,182,183]. 
 
Table 3.2 Approved antiangiogenic VEGF inhibitors and their indications. 
 US FDA approval year EMA approval year Comments 
Bevacizumab    
Metastatic 
colorectal cancer 
2004 (first line); 2006 
(second line) 















2009 2005 With interferon 
Ovarian cancer 2014 for platinum-
resistant recurrent ovarian 




2012 for first-line and 
platinum-sensitive 
recurrent 
ovarian cancer; 2014 for 
platinum- resistant 
recurrent ovarian cancer 
With 
chemotherapy 
Breast cancer Withdrawn 2009 With 
chemotherapy 
Aflibercept    
Colorectal 
cancer 
2012 2013 Second line 
Adapted from Jayson GC et al. [184]. EMA = European Medicines Agency. 
 
VEGF-A alternative splicing has been studied previously [185], and VEGF gene 
comprises of eight exons. Alternative splicing of VEGF produces different isoforms including 
three dominant forms such as VEGFA-165, VEGFA-121 and VEGFA-189 overexpressed in 
various types of solid cancers (Figure 3.1). However, AO-mediated VEGF exon-skipping as a 





Figure 3.1 Alternative splicing of VEGF-A gene. The gene is spliced into different isoforms 
including the most dominant VEGFA-121, 165 and 189. Adapted from Nowak et al., 2008 
[177]. 
 
Application of AO to manipulate pre-mRNA splicing has been extensively studied in 
Duchenne muscular dystrophy [186]. So far, there is only one report in using exon-skipping 
for cancer therapy [187]. In this study, we envisioned this approach to develop exon-skipping 
AOs targeting VEGF-A to inhibit functional VEGF-A expression towards tackling cancer cell 
proliferation and metastasis. We hypothesized that by developing a single AO targeting one of 
the key VEGF-A exons, all dominant VEGF-A isoforms can be inhibited simultaneously, and 
can therefore be a unique approach to significantly improve the efficacy of VEGF targeting 
therapy. We designed the exon-skipping AOs (Table 3.3) targeting various exons of the VEGF-
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A pre-mRNA including exon 2, 3, 4, 5, 7 as shown in the VEGF-A exon map (Figure 3.2) to 
down-regulate the expression of VEGF-A protein isoforms simultaneously. Based on our 
study, we herein reported for the first time that the use of splice-switching AOs to efficiently 
down-regulate VEGF-A through exon-skipping approach. 
 
 
Figure 3.2 VEGF-A gene comprises of 8 exons. The gene is then spliced into different 
isoforms including the three most dominant VEGF-165, 121 and 189.  
 
Table 3.3 AOs designed to target VEGF-A pre-mRNA across exon 2, 3, 4, 5, 7.* 
Exon 
(size) 
Name Sequence (5’-3’) No. 
2 
(52bp) 
VEGFA-2A(-14+11) GCCUGGGACCAcugaggacagaaag 1 
VEGFA-2A(+6+30) UCCUUCUGCCAUGGGUGCAGCCUGG 2 
VEGFA-2A(+22+46) GAUGAUUCUGCCCUCCUCCUUCUGC 3 








VEGFA-3A(-14+11) GAACUUCACCAcugcaugagaggcg 5 
VEGFA-3A(+8+32) GCUGCGCUGAUAGACAUCCAUGAAC 6 
VEGFA-3A(+26+50) CUCGAUUGGAUGGCAGUAGCUGCGC 7 
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VEGFA-3A(+40+64) AUGUCCACCAGGGUCUCGAUUGGAU 8 
VEGFA-3A(+57+81) CAGGGUACUCCUGGAAGAUGUCCAC 9 
VEGFA-3A(+84+108) AUGGCUUGAAGAUGUACUCGAUCUC 10 













VEGFA-4A(+5+29) UGGCCUUGGUGAGGUUUGAUCCGCA 15 
VEGFA-4A(+28+52) GGAAGCUCAUCUCUCCUAUGUGCUG 16 




VEGFA-5A(-5+20) UUGCUCUAUCUUUCUUUGGUcugca 18 




VEGFA-7A(+18+42) ACAAACAAAUGCUUUCUCCGCUCUG 20 
VEGFA-7A(+46+70) GGAACAUUUACACGUCUGCGGAUCU 21 
VEGFA-7A(+97+121) AACUCAAGCUGCCUCGCCUUGCAAC 22 
*Chemistry: fully-modified 2’-OMePS except AO4-PMO. Uppercase letters represent part of 
the AO targeting exonic region, lower case letters represent part of the AO targeting intronic 
region. 
 
3.2 Experimental procedure 
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3.2.1 Design and synthesis of AOs   
The 2'-O-Methyl AOs (Table 3.3) were designed and synthesised in-house on a 
phosphorothioate backbone using GE AKTA Oligopilot 10 synthesiser (GE Healthcare Life 
Sciences, Parramatta, NSW, Australia) via standard phosphoramidite chemistry in 1 µmol 
scale. The synthesised oligonucleotides were deprotected and cleaved from the solid support 
by treatment with NH4OH at 550C overnight. The crude oligonucleotides were then purified, 
desalted and verified by polyacrylamide gel electrophoresis. AO4-PMO was ordered from 
Gene Tools (Philomath, Oregon, USA).  
 
3.2.2 Cell culture and transfection 
Human cancer cell lines including DAOY (HTB-186), triple-negative breast cancer cell line 
MDA-MB231 (HTB-26) were obtained from American Type Culture Collection (Manassas, 
VA, USA); maglinant mesothelioma cell line ONE58 (CBA-0143) was obtained from Cell 
Bank Australia (Westmead, NSW, Australia). All three cell lines were cultured in 10% Fetal 
Bovine Serum (FBS) Dulbecco’s Modified Eagle’s Medium (DMEM) (Thermo Fisher 
Scientific, Scoresby, VIC, Australia) in a humidified atmosphere at 37 0C, 5% CO2. Cells were 
cultured to reach 70-90% confluency, then seeded at a density of 2.5×104 (cells/ml) for DAOY, 
1×105 (cells/ml) for MDA-MB231 and 5×104 (cells/ml) for ONE58 into 24-well plates 
(Thermo Fisher Scientific) 24 hours prior to transfection. Next, the exon-skipping AOs were 
transfected at 400 nM concentration for initial screening using Lipofectamine 3000 transfection 
reagent following the manufacturer’s protocols. It was also noted that the best performing AO 
(AO4) was then transfected using the same protocol but at lower doses at 5, 10, 25 and 50 nM. 
Twenty-four hours after transfection, the cells were collected for RNA extraction. 
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In addition, AO4-PMO was transfected into DAOY cells at 50, 250 and 1250 nM final 
concentrations by nucleofection method using Primary P3 Nucleofection kit (Lonza, Waverley, 
VIC, Australia). Briefly, for each treatment, 6×105 cells were trypsinised, centrifuged and 
resuspended in Nucleofection master mix following manufacturer’s protocol. Then, the cells 
were nucleofected with AO4-PMO using program CA-137 by 4D-Nucleofector system X-unit 
(Lonza). Cells were collected either at 3 days or 5 days timepoints for further analysis. 
 
3.2.3 RNA extraction and RT-PCR 
RNA was extracted from transfected cells using Direct-zol™ RNA MiniPrep Plus with TRI 
Reagent® (Zymo Research, supplied through Integrated Sciences, Chatswood, NSW, 
Australia) as per the manufacturer’s instructions. The VEGF-A products were amplified using 
the primer set shown in Table 3.4 with SuperScript® III One-Step RT-PCR kit (Thermo Fisher 
Scientific). Briefly, the conditions were 55 0C, 30 minutes; 94 0C, 2 minutes following by 34 
cycles of 94 0C, 1 minute, 58 0C, 30 seconds and 68 0C, 1 minute. The PCR products were then 
separated on a 3% agarose gel in Tris–acetate–EDTA buffer and visuallised with Fusion Fx gel 
documentation system (Vilber Lourmat, Marne-la-Vallee, France). It was noted that VEGF-A 
skipped product size was calculated by subtracting the original PCR product size with exon-2 
(52bp). Densitometry was performed by Image J software. The actual exon-skipping efficiency 
was determined by expressing the amount of exon-2 skipped RT-PCR product as a percentage 
of total VEGF-A transcript products. 
 
Table 3.4 Primer sequences used in this study. 




VEGFA-Ex6R (1783-1764) CTTCCGGGCTCGGTGATTTA 
 
3.2.4 Bandstab and sequencing 
Bandstab technique was performed in line with the previous published procedure [188]. The 
bandstab samples were then amplified with the same primer set (Table 3.4) using AmpliTaq 
Gold® DNA Polymerase kit (Thermo Fisher Scientific). Briefly, the conditions were 94 0C, 6 
minutes following by 35 cycles of 94 0C, 30 seconds, 52 0C, 1 minute and 72 0C, 2 minutes. 
PCR products were confirmed by 3% agarose gels and sent for sequencing using both the 
forward primer and reverse primer (Table 3.4). 
 
3.2.5 Western blot 
Western blotting was performed to evaluate the effect of AO4-PMO towards the inhibition of 
VEGF protein in comparison with the untreated sample. Frozen transfected cell pellets were 
thawed and homogenised in SDS lysis buffer (0.5 M Tris-HCl pH 6.8, 3% SDS (w/v) and 10% 
glycerol (v/v)) containing protease inhibitor (Sigma, Castle Hill, NSW, Australia). The 
homogenate was then centrifuged at 14,000 g for 3 minutes, after which the supernatant was 
removed, and the protein concentration of the supernatant was estimated using Pierce™ BCA 
Protein Assay Kit (Thermo Fisher Scientific). Protein from the samples was then resolved on 
a 10% SDS polyacrylamide gel under reducing conditions and electro-transferred onto a 
nitrocellulose membrane (Bio-Rad, Gladesville, NSW, Australia). The membrane was 
processed with primary anti-VEGF antibody (1:1000) (ab46154, Abcam, Melbourne, VIC, 
Australia) and secondary anti-rabbit HRP antibody (1:10000) (Cat. 31460, Thermo Fisher 
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Scientific) using iBind Flex Western Device (Thermo Fisher Scientific) following 
manufacturer’s instructions. The protein bands were visualized with a chemiluminescence-
based procedure using the Clarity Western ECL detection kit according to the manufacturer's 
protocol (Bio-Rad).  
 
3.2.6 Cell viability assay 
To evaluate the non-specific effects of the AO candidate, normal human fibroblast cells were 
seeded at 1.5×104 (cells/ml) and transfected with AO4 as described previously. After 24 hours, 
cell viability assay was performed using a colorimetric assay (WST-1, Sigma-Aldrich). Briefly, 
WST-1 solution was added at ratio 1:10 (v/v) per well and incubated for 4 hours at 37 °C, 5% 
CO2. The absorbance was then measured with a microplate reader (FLUOstar Omega, BMG 
Labtech, Germany) at 450 nm. 
 
3.3 Results and Discussions 
3.3.1 Exon-skipping was achieved at various levels with different AOs targeting exon 2, 
3, 4, 5, 7 in VEGF-A transcript in a triple-negative breast cancer cell line  
We have initially screened the designed AOs in a triple-negative breast cancer cell line MDA-
MB231 at 400 nM concentration. RT-PCR results clearly showed efficient skipping of VEGF-
A dominant isoforms such as 165 and 121, especially those targeting exon 2 by yielding the 
skipped products of 816 bp for exon-2 skipped VEGFA-165, and 684 bp for exon-2 skipped 
VEGFA-121, in comparison to full-length products of 868 bp (VEGFA-165) and 736 bp 





Figure 3.3 RT-PCR analysis showing the screening results of various exon-skipping 
induced by AOs shown in Table 3.3 in VEGF-A transcript in MDA-MB231 (triple-
negative breast cancer cell line) at 400 nM. UT = untreated, -ve = negative, 2% agarose gel. 
 
3.3.2 Exon 2 was efficiently skipped in VEGF-A transcript when treated with AOs in 
various types of solid cancers 
We then screened the AOs specifically targeting exon 2 (Table 3.5) in DAOY 
(medulloblastoma cell line). Briefly, the cells were plated 24 hours allowing to reach optimum 
confluency before transfecting with the AOs. For this experiment, we hypothesized that higher 
exon-skipping efficiency could be achieved by increasing AO concentration, therefore, AO1, 
2, 3, 4 targeting exon 2 were transfected at 400, 600 and 800 nM concentrations to DAOY cells 




Table 3.5 AOs targeting exon 2 in VEGF-A transcript* 
Name Chemistry Sequence (5’-3’) No. 
VEGFA-2A(-14+11) 2’OMePS GCCUGGGACCAcugaggacagaaag 1 
VEGFA-2A(+6+30) 2’OMePS UCCUUCUGCCAUGGGUGCAGCCUGG 2 
VEGFA-2A(+22+46) 2’OMePS GAUGAUUCUGCCCUCCUCCUUCUGC 3 






*Uppercase letters represent part of the AO targeting exonic region of exon 2, lower case letters 
represent part of the AO targeting intron 2-3. 
 
The RT-PCR results clearly showed that AO2-4 efficiently skipped exon 2 of the VEGF-
A dominant isoforms such as 165 and 121 at all concentrations, and VEGFA-2D (+7-18) (AO4) 
was found to be the best to induce exon 2-skipped product of 816 bp (VEGFA-165) and 684 bp 
(VEGFA-121) based on replication and densitometry analysis (data not shown) (Figure 3.4). 




Figure 3.4 RT-PCR analysis showing the results of exon-2 skipping induced by AOs 
targeting exon 2 in VEGF-A transcript in DAOY (medulloblastoma cell line) at 400, 600 
and 800 nM concentrations. The triangles above the gel images indicate increasing AO 
concentration (400, 600 and 800 nM). Scrambled control AO: 5’- 
CCUCUUACCUCAGUUACAAUUUAUA - 3’. UT = untreated, -ve = negative, 2% agarose 
gel. 
 
Next, the efficacy of AO4 was further evaluated in various cancer cell lines including 
DAOY (medulloblastoma), ONE58 (Mesothelioma), MDA-MB231 (triple-negative breast 
cancer) at lower concentrations (5, 12.5, 25 and 50 nM) using the same protocol described 
above. RT-PCR results showed that AO4 effciently skipped exon 2 from the VEGF-A dominant 
isoforms such as 165, 121 and 189 by yielding the skipped product of 816 bp, 684 bp and 888 
bp from VEGFA-165, 121 and 189 transcripts, respectively (Figure 3.5). Densitometry analysis 




Figure 3.5 VEGF-A isoforms 165, 121, 189 exon-2 were efficiently skipped when treated 
with the AO candidate AO4. The triangles above the gel images indicate increasing AO 
concentration (5, 12.5, 25 and 50 nM). Scrambled control AO: 5’- 
CCUCUUACCUCAGUUACAAUUUAUA - 3’. UT = untreated, -ve = negative, 3% agarose 
gel. 
 
Table 3.6 Percentage of exon-2 skipping in various solid cancer cell lines by transcript 
densitometry analysis. 
 DAOY ONE58 MDA-MB231 
 165 121 189 165 121 189 165 121 189 
5nM 44 40 17 48 43 29 58 55 64 
150 
 
10nM 64 58 57 60 53 45 75 69 84 
25nM 84 87 90 67 62 53 81 77 91 
50nM 89 83 95 65 58 50 76 69 84 
 
To further confirm the skipped product, sequencing analysis was performed. For this 
purpose, agarose gels were utilised to isolate the samples by band-stab technique which was 
then amplified and sequenced. The sequencing data was analysed using BioEdit software 
(available at http://www.mbio.ncsu.edu/BioEdit/bioedit.html) demonstrated the skipping of 
exon 2 in a base-specific manner (Figure 3.6A and B). 
 
 
Figure 3.6 Sequencing data analysis of exon 2 skipped products using AO4. A. Alignment 





Skipping of exon 2, in principle, will induce a stop codon in exon 3. Not surprisingly, the 
sequencing data confirmed that the skipped product contain a stop codon starting at nucleotide 
4 of exon 3 (Figure 3.7), which will lead to translational arrest. 
 
 
Figure 3.7 A closer look at the stop codon in exon 3 resulted from exon 2 skipping in 
VEGF-A transcript. A. Untreated product; B. Exon 2-skipped product. 
 
3.3.3 VEGF-A is down-regulated at protein level when treated with exon-skipping AO 
in a medulloblastoma cell line 
As demonstrated above, AO4 composed of 2’-OMePS chemistry was very effective in skipping 
exon 2 at the RNA level. However, in order to validate the efficacy of AO4 to inhibit the 
expression of VEGF-A at protein level, it is advised to use the exon-skipping AO4 with PMO 
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chemistry. Based on this literature report [189], we then obtained AO4 with PMO chemistry 
(AO4-PMO) (Table 3.5) and tested the skipping efficiency in DAOY cell line. The cells were 
plated onto T25 flasks 24 hours prior to nucleofection. Next day, the AO was nucleofected into 
cells using Lonza nucleofection system unit X at 50 nM, 250 nM and 1250 nM final 
concentrations. Then, the cells were harvested after 3 days and 5 days and the samples were 
divided for both RNA extraction and western blot analysis. The RNA extraction and RT-PCR 
were performed as mentioned above. The gel results clearly showed that exon-2 was efficiently 
skipped in the VEGF-A transcripts in both 3 days and 5 days of incubation (Figure 3.8). 
 
 
Figure 3.8 RT-PCR analysis showing the results of exon-2 skipping induced by AO4-
PMO in VEGF-A transcript. A. 3 days-time point; B. 5 days-time point. The triangles above 
the gel images indicate increasing AO concentration (50, 250 and 1250 nM). UT = untreated, 





Based on the successful exon 2 skipping results, western blot was then performed to 
determine the protein level of VEGF-A after the AO treatment. Briefly, the protein samples 
were run on the SDS 10% gel and transferred to a nitrocellulose membrane. Then, the VEGF-
A primary antibody (1:1000) and secondary HRP antibody (1:2000) were added to the iBind 
Flex Western Device for 2.5 hours before visualised by chemiluminescence using ECL 
substrate. The results demonstrated that the VEGF-A protein was downregulated in the treated 
samples and the effect was most obvious after 5 days-time point (Figure 3.9A). Densitometry 
analysis by Image J software revealed that at 5 days-time point, the VEGF protein was down-
regulated 9%, 47% and 83% in comparison to the untreated sample (Figure 3.9B). 
 
Figure 3.9 Western blot gel image showing the results of VEGF protein downregulation 
after exon-2 skipping in DAOY cells. A. Western blot gel image visualised by 
chemiluminescence; B. Densitometry analysis of the western blot gel image demonstrating 
down-regulated percentage of VEGF-A protein in treated samples at 5 days post transfection 
of AO4-PMO. The triangles above the gel images indicate increasing AO concentration (50, 
250 and 1250 nM). UT = untreated. 
 
3.3.4 VEGF-A targeting AO candidate showed no toxicity when treated with non-
cancerous cells (normal human fibroblast) 
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To evaluate the toxicity of AO4 in non-cancerous cells, normal human fibroblasts were seeded 
and transfected with the AO at 5, 10, 25 and 50 nM. Twenty-four hours post-treatment, cell 
viability assay was performed to access the toxicity effect of the AO. The RT-PCR analysis 
showed efficient skipping of exon 2 in VEGF dominant isoforms such as 165, 121 and 189. 
Interestingly, normal human fibroblasts viability was maintained at 95% when treated with 50 
nM AO concentration, showing negligible toxicity to cells (Figure 3.10). 
 
 
Figure 3.10 AO4 treatment in normal human fibroblasts showed A. Efficient exon-
skipping and B. No toxicity detected (by WST-1 assay). The triangles above the gel images 
indicate increasing AO concentration (5, 12.5, 25 and 50 nM). C = Scrambled control oligo, 
UT = untreated, -ve = negative, 3% agarose gel. 
 
3.4 Discussions 
The ultimate goal of modern healthcare development towards solid cancers treatment is to 
develop agents that selectively target disease-specific sites within the body with high efficacy, 
no toxicity or side effects, at low cost. In this study, we reported for the first time the use of 
AO synthesised “in-house” to induce VEGF-A exon-skipping in various cancer cell lines such 
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as DAOY (medulloblastoma), ONE58 (Mesothelioma), MDA-MB231 (triple-negative breast 
cancer). Of these AOs, AO4 showed efficient skipping of exon 2 in VEGF-A165 and VEGF-
A121 pre-mRNA transcripts, and resulted in the induction of a pre-mature stop codon at the 
beginning of exon 3, which lead to translational arrest. PMO chemistry has demonstrated 
excellent safety profile which has been studied extensively in Duchenne muscular dystrophy 
clinical trials [190]. The AO candidate AO4 was also obtained with PMO chemistry (AO4-
PMO) and confirmed to efficiently induce exon-skipping in DAOY medulloblastoma cell line. 
Western blot results showed that VEGF protein was down-regulated of up to 83% after 5 days 
of treatment with AO4-PMO. This promising outcome encourages us to evaluate the efficacy 
of AO4-PMO in in vivo model. 
Neovascularisation in the eyes is implicated in diseases such as wet aged-macular 
degeneration (AMD), diabetic retinopathy (DR) and diabetic macular edema (DME) [191-
194]. The overgrowth of blood vessels in the eyes is the main cause of blood leakage which 
can result in vision loss and blindness. Macugen is an anti-VEGF aptamer approved by US 
FDA in 2004 for the treatment of wet AMD [195,196]. By binding to VEGF-165 isoform as 
an antagonist, Macugen reduces the growth of blood vessel and improves the disease condition. 
Towards this, exon-skipping AO targeting VEGF transcript might be a feasible approach to 
simultaneously inhibit all dominant isoforms of VEGF efficiently. Therefore, further testing of 
AO4 in wet AMD, DR and DME models would be another promising therapeutic strategy, 
given the delivery is non-invasive and effective. A comprehensive review on the drug delivery 
to the eyes such as encapsulated cell technology, colloidal drug carriers and pulsed high-
intensity delivery can be found elsewhere [197]. 
Recently, a VEGF-targeting aptamer (V7t1) was shown to effectively bind to VEGF-A165 
and VEGF-A121 protein [198]. Soon after, a chemically-modified version of V7t1, named 
RNV66, containing three Locked Nucleic Acid (LNA) nucleotides [199], also demonstrated 
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efficient inhibition of breast cancer cell proliferation [200]. In line with this, a combination of 
AO4 and RNV66 for dual targeting of VEGF at both RNA and protein levels can be a viable 
approach for efficient VEGF targeting cancer therapy. In addition, chemically-modified 
monomers such as Locked Nucleic Acid (LNA) and Unlock Nucleic Acid (UNA) [201-203] 
can be strategically introduced into the 2’-OMePS AO for binding affinity and stability 
improvement which enhances the AO pharmacokinetics. 
 
3.5 Conclusion 
Angiogenesis plays a vital role in cancer initiation, development, migration and metastasis. 
This complex process is regulated by a number of growth factors and angiogenesis markers. 
The discovery of various markers and their functions has opened up new horizons in cancer 
research with novel approaches and multiple targets for developing cancer therapeutics. 
Antisense oligonucleotide-based therapy has emerged as a feasible RNA targeting therapeutic 
strategy for tackling different diseases and the number of antisense-based drugs approved by 
the US FDA such as Vitravene, Kynamro, Exondys51 and Spinraza validates the scope of this 
approach and highlights the significance of developing AO-based therapy for cancer. In this 
study, an exon-skipping AO candidate targeting VEGF pre-mRNA transcript was developed. 
By efficiently skip exon-2 in the VEGF-A transcript and inhibit all predominant VEGF-A 
isoforms simultaneously, AO4 (AO4 PMO) showed significant down-regulation of VEGF 
mRNA in various solid cancer cell lines such as DAOY (Medulloblastoma), ONE58 
(Mesothelioma) and MDA-MB231 (Triple-negative breast cancer). AO4 (AO4 PMO) also 
showed efficient inhibition of VEGF-A protein level after 5 days of treatment in vitro. 
Although further evaluation in in vivo model is required, AO4 (AO4 PMO) is believed to be a 
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novel therapeutic molecule for tackling solid cancers and the application might be extended to 
other diseases such as wet AMD, DR and DME. 
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Nucleic acid-based therapeutics are emerging as potential treatment for various genetic 
diseases. The technology is paramount to specifically target the pathology hallmark of the 
disease at RNA or protein levels, thereby achieving the optimal treatment outcome. In the last 
two decades, the tremendous demand for a highly efficient drug with no side effects have driven 
a great number of studies aiming at synthesising novel nucleic acid analogues for this purpose. 
In line with that, the major focus of this thesis is to design and evaluate novel chemically-
modified antisense oligonucleotides incorporated with different types of nucleic acid 
monomers in the search for better alternatives that can be utilised in drug development.  
We have demonstrated the design and synthesis of AOs composed of modified nucleotides 
including locked nucleic acid, anhydrohexitol nucleic acid, cyclohexenyl nucleic acid, D-
altritol nucleic acid, twisted intercalating nucleic acid, serinol nucleic acid and 5-
(phenyltriazol)-2′-deoxyuridine. To evaluate the AOs, an in vitro disease model of Duchenne 
muscular dystrophy was used as our biological platform, and the modified AOs were assessed 
for their efficiency in inducing exon-skipping, their stability against nuclease degradation and 
possible cytotoxicity to cells. Our findings showed remarkable achievements that contribute to 
the existing knowledge of the field of antisense research. One of which is the rational design 
of short AOs incorporated with LNA monomers to minimise the toxic effects of 2’OMePS AO 
while not compromising the efficacy. We found that a 14-mer LNA/ 2’-OMePS AO is capable 
of induce exon-skipping that is on-par with a 20-mer fully 2’-OMePS AO, which is promising 
to be further investigated in in vivo models and clinical trials. Another example is the use of 
twisted intercalating nucleic acid in exon-skipping application. Although the results did not 
favour the TINA-modified AOs in term of exon-skipping, our data suggested that placing the 
TINA monomer towards 5’-end might increase the skipping efficiency, however, adding 
another TINA monomer at 3’-end decrease the efficacy while enhanced the AO stability. 
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Therefore, fine-tuning the balance between efficacy and stability would be a critical point that 
should be considered during nucleic acid drug development.  
To further demonstrate the application of exon-skipping AO, we designed a set of 2’-
OMePS AOs against vascular endothelial growth factor (VEGF) towards tackling solid cancers 
and other VEGF-related diseases such as aged-macular degeneration, diabetic retinopathy and 
diabetic macular edema. These AOs were tested for their efficacy in different cancer cell lines 
such as DAOY medulloblastoma cell line and MDA-MB231 breast cancer cell line where the 
best candidate (Vexsa2) showed inhibition of up to 83% of VEGF expression at protein level, 
while showed no toxicity to normal human fibroblast. These data encourage us to move forward 
in testing Vexsa2 in other disease models implicated by VEGF over-expression. 
 In conclusion, the findings in this thesis highlight the enormous potential of chemically-
modified nucleic acid analogues in oligonucleotide-based therapeutic applications especially 
in exon-skipping. The need of an efficient, affordable and non-toxic drug has opened up the 
scope for additional modified nucleotides to be synthesised and evaluated. We hope that our 
works can benefit the advancement in the field of antisense research by gaining more insights 





Appendix 1: Oligonucleotide synthesis materials and methods 
Materials 
All instruments and reagents used for oligonucleotide synthesis in this thesis are listed below. 
Table A1. Instruments used for oligonucleotide synthesis in this thesis. 
Instrument name  Catalogue number Company 
ÄKTA Oligopilot Plus 10 18114042 GE Life Sciences 
ABI Expedite® 8909 Nucleic Acid Synthesis 
System 
 Applied Biosystems 
Applied Biosystems Voyager-DE Pro  Applied Biosystems 
C20S Compact Karl Fischer Coulometer C20SX Mettler Toledo 
Heraeus Oven T12 Thermo Fisher Scientific 
Fume control system FE2000 Johndec 
Mini-PROTEAN Tetra Cell 1660827EDU Bio-Rad Laboratories 
NanoDrop 1000 Spectrophotometer ND-1000 Thermo Fisher Scientific 
PowerPac 3000  Bio-Rad Laboratories 
Precision balance GR-300 A&D 
Shimadzu UV-1800 Spectrophotometer 206-23900-58 Shimadzu 
Vilber Lourmat Fusion FX7  Vilber Lourmat 
Weighing balance GX-4000 A&D 
 
Table A2. Reagents used for oligonucleotide synthesis in this thesis. 
Item Name Catalogue Number Company name 
2-Propanol 437522 Sigma 
2'-OMe rA (n-bz) phosphoramidite ANP-5751 ChemGenes 
2'-OMe rC (n-bz) phosphoramidite ANP-5752 ChemGenes 
2'-OMe rG (n-ibu) phosphoramidite ANP-5753 ChemGenes 
2'-OMe rU phosphoramidite ANP-5754 ChemGenes 
3-Methyl Pyridine P42053 Sigma 
5-Benzylthio-1H-tetrazole  B3020 TCI Chemicals 
6-Aza-2-thiothymine 275514 Sigma 
Acetonitrile UV Anhydrous CA1925 Sigma 
Acetonitrile HPLC grade 600095 Thermo Fisher Scientific 
Ammonium citrate tribasic A1332 Sigma 
Ammonium Hydroxide 221228 Sigma 
Ammonium persulfate A3678 Sigma 
Baxter sterile water 2F7114 Baxter  
Boric acid B0252 Sigma 
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Capping Reagent A CC0899 Merck 
Capping Reagent B 8570120200 Merck 
Combi Coulomat fritless Karl Fischer 1092570500 Merck 
DCI Activator L032000 Sigma 
Dichloroacetic Acid D54702 Sigma 
Dimethylamine Anhydrous CD1267 Sigma 
EDTA disodium salt dihydrate E5134 Sigma 
Frits- 017-040018 6mm 18-45 um mesh size 017-040018 HTI Bio-x GmbH 
Frits- 017-040020 6.3 mm 18-45 um mesh 
size 
017-040020 HTI Bio-x GmbH 
Glen UnySupport™ FC 22-5041-10 Glen Research 
illustra NAP-10 Columns 17085401 GE Life Sciences 
Leur Style Empty Synthesis Column w/Frits, 
1 micromole, Clear 
MLX-6030-C BioAutomation 
Molecular Sieves, 3 Angstrom, beads, 4-8 
Mesh 
208582 Sigma 
Molecular Sieves, 4 Angstrom, beads, 4-8 
Mesh 
208590 Sigma 
N,N,N′,N′-Tetramethylethylenediamine T9281 Sigma 
Oxidizer 0.05M Iodine for ÄKTA L060050 Sigma 
Oxidizer 0.02M Iodine for Expedite™ L860020-06 Sigma 
Phenylacetyl Disulfide 554324 Sigma 
40 % Premixed Acrylamide Solutions (29:1) 161-0147 Bio-Rad Laboratories 
Primer Support Packing Kit 18103519 GE Life Sciences 
Pyridine anhydrous 270970 Sigma 
Reagent Alcohol 362808 Sigma 
SYBR™ Gold Nucleic Acid Gel Stain S11494 Thermo Fisher Scientific 
10x TBE buffer  Made in-house with 1 M 
Trizma base, 1 M Boric 
acid, 0.02 M Na2EDTA, 
top up to 1 L with deionised 
H2O. 
TCA Deblock L020080 Sigma 
Toluene AR grade 2.5L 1083252500 Sigma 
Trizma® base T1503 Sigma 
Urea U1250 Sigma 
Xanthane Hydride X0001 TCI Chemicals 
 
Methods: 
Oligonucleotides (oligos) were synthesised in-house via standard phosphoramidite chemistry 
in 1 μmol scale. Synthesis performed on ÄKTA Oligopilot Plus 10 was monitored using 
UNICORN™ 5.31 software, while the synthesis performed on ABI Expedite® 8909 Nucleic 
Acid Synthesis System was controlled directly on the instrument built-in interface. The 
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synthesis procedure is similar for both instrument regarding the description below. Firstly, 
empty column was packed with 25 mg of Glen UnySupport™ FC (Glen Research, VA, USA) 
following the manufacturer’s protocol. The column cassette was then washed with Acetonitrile 
and inserted into the column reactor. The synthesis was monitored automatically by the 
instrument software.  
Post-synthesis, deprotection step was carried out by incubating the column with 
Ammonium hydroxide for 8 hrs at 55 οC before desalted by illustra NAP-10 Columns (GE Life 
Sciences, NSW, Australia). The oligo was measured the concentration with NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, VIC, Australia) before checking the purity by 
MALDI-TOF mass spectrometry using Applied Biosystems Voyager-DE Pro system (Applied 
Biosystems, CA, USA). Briefly, the matrix was prepared by mixing Ammonium citrate tribasic 
(20 mM) with Acetonitrile (v/v = 1:1) and added with 10 mg/ml of 6-Aza-2-thiothymine. Then, 
1 µl of oligo sample (5 µM) was mixed with 3 µl of the matrix, loaded onto the matrix plate 
(in duplicate) and kept in vacuum desiccator for 10 mins before analysed with the mass 
spectrophotometer system.  
Alternatively, denaturing polyacrylamide gel electrophoresis (PAGE) can also be used for 
checking the oligo purity. Firstly, 20 % denaturing gel mix was prepared by mixing 40 % 
Premixed Acrylamide Solutions (29:1) (Bio-Rad Laboratories, NSW, Australia) with 7 M of 
Urea and top up with deionized H2O. Prior casting, gel mix was added with Ammonium 
persulfate (Sigma, NSW, Australia) and N,N,N′,N′-Tetramethylethylenediamine (Sigma) 
before casted using Mini-PROTEAN Tetra Cell (Bio-Rad Laboratories) following the 
manufacturer’s protocol. Upon solidified, gel was pre-run in 1x TBE buffer at 13W for 30 
mins, then samples were loaded, run for 30 mins at the same power, stained with SYBR™ Gold 
Nucleic Acid Gel Stain (Thermo Fisher Scientific) and analysed by Vilber Lourmat Fusion 
FX7 imaging system (Vilber Lourmat, Collégien, France).  
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